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Abstract 
The role of family nurse practitioners (FNPs) in promoting medication adherence in 
adolescents with inflammatory bowel disease (IBD) has not been established. This project 
provides intervention strategies that FNPs can use to promote oral medication adherence to 
maintenance treatment in adolescents with IBD. This is a critical need because non-adherence to 
maintenance therapy is the most significant factor associated with relapses of IBD and a serious 
health issue in adolescents with illD. There are no current best practice guidelines in promoting 
adherence to maintenance medications in illD patients. Findings from the literature review 
suggest that non-adherence to maintenance therapy is complex and multi-factorial. No single 
intervention strategy has been shown to be effective for all patients and conditions. However, 
individually tailored interventions that attend to behavioural, educational and psychosocial 
factors appear promising. The bio-psychosocial model is used as a conceptual framework to 
examine the factors affecting medication adherence and to explore the intervention strategies for 
improving medication adherence. Findings of this project are limited by the paucity of research 
on medication adherence in adolescents with illD. Implications and recommendations for family 
nurse practitioner practice, education and research are discussed. 
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1 
Introduction 
Inflammatory bowel disease (IBD) is a chronic, autoimmune disease of the 
gastrointestinal tract characterized by clinical remissions and unpredictable relapses. The peak 
onset ofiBD coincides with adolescence, as the median age of diagnosis is age 15, and 
approximately 25% of IBD occurs before the age of 20 years (Kappelman et al., 2007). 
According to Crohn's and Colitis Canada (CCC), Canada has one of the higher rates ofiBD in 
the world, with the number of new cases of IBD in Canadian children almost doubling since 
1995 (CCC, 2014). 
The management of IBD aims to induce and maintain a clinical remission, prevent 
disease relapse and improve quality of life. Pharmacological interventions represent the 
cornerstone of management for IBD by targeting the underlying inflammatory response 
(Diefenach & Breuer, 2006). Life long maintenance therapy is required to prevent relapses of the 
disease and colorectal cancer (Zheng & Kennedy, 2009). Successful management ofiBD 
necessitates adherence to maintenance medications. The demands of adhering to maintenance 
medications are perceived as a major burden by adolescents (Leleiko et al., 2013). 
Non-adherence to maintenance medications is the most significant factor associated with 
relapses of IBD. No studies have reported the impacts of non-adherence to maintenance 
medications on relapse rates of the disease in an adolescent population. In adult patients with 
IBD, non-adherence resulted in more than a five times greater risk of relapses of the disease than 
adherent patients (Kane, Huo, Aikens, & Hanauer, 2003). Adherence to maintenance 
medications has significant implications for prevention of complications and morbidities, 
improvement of disease outcomes and quality of life, and reduction in healthcare costs 
(Hawthorne, Rubin, & Ghosh, 2008; Hommel, Denson, & Baldassano, 2011; Home, Parham, 
Driscol, & Robinson, 2009; Quittner, Modi, Lemanek, Levers-Landis, & Rapoff, 2008). 
Therefore, improving medication adherence is an important step in the effective management of 
IBD in adolescents. 
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Promoting medication adherence in adolescents with IBD is challenging for healthcare 
providers, in part because best practice in promoting medication adherence is not well defmed. 
As primary care providers, family nurse practitioners (FNPs) have a role in promoting 
medication adherence and improving the quality of care for adolescents with IBD. A review of 
the literature in this area is timely to identify best practice for FNPs to promote medication 
adherence. A holistic approach is essential to develop strategies to identify adolescents at risk for 
non-adherence and provide effective interventions to improve adherence. 
A conceptual framework can provide a useful lens to examine and analyze literature. The 
bio-psychosocial (BPS) model is chosen for this paper to explore the role of FNPs in promoting 
medication adherence in adolescents with IBD. The BPS model suggests that healthcare 
professionals take into account the interactions of psychological, social factors and biological 
processes to fully understand disease progression and changes (Engel, 1980). The bio-
psychosocial perspective provides a comprehensive approach to frame effective promotion of 
medication adherence in adolescents with IBD. 
The World Health Organization (WHO) defmes an adolescent as any person between the 
ages of 1 0 and 19 ,and adolescence is marked by a transitional phase of growth and development 
between childhood and adulthood (WHO, 2014). During this transitional period oflife, 
adolescents undergo profound changes in biologic, social and psychological realms and also 
experience role changes within family and peer groups. It is a time when adolescents strive to 
become more independent, along with increased academic and social demands (Mamula, 
Markowitz, & Baldassano, 2003). 
Compounded with the developmental characteristics of adolescence, medication 
adherence in adolescents becomes complex and challenging. Adolescents with IBD are 
susceptible to anxiety/depressive symptoms, and thus can experience greater difficulties with 
adherence to IBD treatment (Gray, Denson, Bladassano, & Hommel, 2012). Adolescents are 
more frequently non-adherent to maintenance treatment than adults with IBD (Kamperidis et al., 
2012). Depending on the medication type and method of assessment, non-adherence rates for 
medications range from 50% to 88% among adolescents with IBD (Hommel, Davis, & 
Baldassano, 2009; Mackner & Crandall, 2005; Oliva-Hemker, Abadom, Cuffari, & Thompson, 
2007). 
3 
Given the prevalence of IBD, along with the high rates of non-adherence in adolescents 
with IBD and the significant impacts of non-adherence on health outcomes and healthcare 
services, there is need to address this issue in FNP practice. The intent of this paper is to explore 
the role ofFNPs in promoting medication adherence in adolescents with IBD by answering two 
questions: 1) in adolescents with IBD, what factors affect their adherence to oral medications for 
maintenance treatment? And 2) what are the intervention strategies that FNPs can use to promote 
oral medication adherence in adolescents with IBD? 
To answer these questions, the context for understanding IBD and maintenance therapy 
in an adolescent population will be first provided, along with definition of adherence and 
methods for assessing medication adherence. The challenges for adolescents adhering to 
medication and the need for promoting medication adherence are also addressed. Second, 
application of the BPS model will be introduced. Third, literature will be reviewed to determine 
and describe factors affecting medication adherence and current intervention strategies for 
improving medication adherence. Through analysis of the literature using the BPS model, 
implications and recommendations for FNP practice, education and future research will be 
presented. 
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Chapter One: Background 
This section aims to provide a context to better understand the disease process, treatment 
regimens and medication adherence. First, an overview ofiBD, maintenance therapy, definition 
of adherence and non-adherence, and methods of measuring medication adherence will be 
presented. Second, the significance of promoting adherence to maintenance medications among 
adolescents with IBD will be addressed. Last, the BPS model will be introduced as a conceptual 
framework to address non-adherence. 
Overview of Inflammatory Bowel Disease 
IBD is a term used for two major gastrointestinal inflammatory disorders: Crohn's 
disease (CD) and ulcerative colitis (UC). IBD is characterized by unpredictable and fluctuating 
cycles of remissions and exacerbations (mild, moderate or severe) throughout a patient's lifetime 
(Higuchi & Bousvaros, 2014). In an adolescent population, IBD presents with unique patterns of 
incidence and clinical manifestations. 
Incidence 
In Canada, the prevalence ofiBD is 1 in 150 compared to 1 in 350 in other nations (CCC, 
20 14). The peak incidence of IBD occurs in patients between the ages of 15 and 25 years, with a 
possible second peak between 50 and 80 years. Approximately 25% to 30% of CD and 20% of 
UC present before the age of 20 years. The incidence of CD is higher than UC in children and 
the incidence of paediatric CD has been increasing, whereas the incidence ofUC has remained 
stable (Dubinsky, 2008; Rufo & Bousvaros, 2006). 
Pathophysiology 
IBD is an immune-mediated inflammatory disease. The aetiology and pathogenesis of 
IBD remain poorly understood. Although the exact pathophysiology of IBD has not been fully 
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defmed, there is both a genetic and environmental component. IBD likely results from a complex 
interaction of genetic, immune and environmental factors (Peppercorn & Cheifetz, 2014). IBD is 
more common in individuals with Jewish ancestry and Caucasians. Approximately 10-25% of 
affected patients have a frrst-degree relative with either UC or CD. Cigarette smoking increases 
the risk for CD but may be protective for the development of UC. It is not certain whether there 
is a direct connection between psychosocial factors and the risk of developing IBD. However, it 
is likely that psychological factors have a role in the exacerbation of symptoms in patients with 
established IBD (Peppercorn & Cheifetz, 2014). 
Clinical Manifestations 
CD and UC share similarities in pathogenesis, symptoms and treatment, but CD can 
involve any part of the gastrointestinal tract fr'?m mouth to anus, most commonly in the ileum 
and ileocecal regions. Inflammation can be focal and transmural from the mucosa to the serosa. 
In UC, the inflammation is superficial and limited to the mucosa of the colon and rectum in a 
diffuse and continuous fashion. Adults and children with IBD have similar gastrointestinal 
symptoms, such as weight loss, abdominal pain, diarrhea, rectal bleeding, or extra-intestinal 
manifestations such as iritis, erythema nodosumor arthritis (Higuchi & Bousvaros, 2014). 
Patients with ffiD have an increased risk of small bowel adenocarcinoma and colon cancer. The 
risk increases with the extent and severity of the disease, the age of onset and duration of the 
disease (Diefenbach & Breuer, 2006). 
When IBD develops earlier in life, there are other challenges that are not encountered 
with the onset of this disease in adults. Challenges found in adolescents with IBD include growth 
and/or sexual maturation impairment, such as subnormal gains in height or weight and delayed 
or failed sexual maturation (Higuchi & Bousvaros, 2014). Moreover, adolescents with IBD have 
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relatively high rates of psychosocial morbidity, such as depression and anxiety. Emotional and/or 
behavioural issues may take the form of child-parent conflict, non-adherence to medications and 
difficulties with school activities or socializing with peers (Mackner, Sission, & Crandall, 2004). 
Goal of Management 
Treatment of IBD is complex, involving medications, dietary modifications and 
sometimes surgery. Currently, there is no permanent cure for IBD. Management ofiBD aims to 
induce and maintain a clinical remission, improve quality of life and decrease the need for 
surgical interventions (Diefenach & Breuer, 2006). The goal of medical management for IBD is 
to achieve clinical and histological remission by suppressing inflammation with a minimum of 
side effects from medications. Once a remission is induced, the patient can be transitioned to 
maintenance therapy, typically involving medications with a slower onset of action and fewer 
side effects (Bousvaros & Leichtner, 2014). 
Surgical intervention usually involves resection of the diseased bowel segment and is 
reserved primarily for patients who do not respond to aggressive medical management, or who 
develop complications. A total colectomy for UC is curative, but most patients do not desire 
surgery. Colectomy and ileoanal reservoirs are an option, but may result in significant 
complications. Elective surgery is generally avoided in CD because of the high recurrence risk. 
Moreover, the intestinal inflammation and extra-intestinal symptoms may occur after surgical 
interventions in both CD and UC (Bousvaros, Leichtner & Burpee, 2014). Therefore, 
pharmacological intervention represents the cornerstone of management for IBD to sustain 
remission by targeting the underlying inflammatory response (Diefenach & Breuer, 2006). 
Maintenance Therapy 
The primary goal of maintenance therapy is to maximize therapeutic efficacy, minimize 
toxicity, maximize medication adherence and quality of life, maintain physical and psychosocial 
wellbeing and prevent disease complications (Dubinsky, 2008). The main oral medications for 
maintaining medically or surgically induced remissions in children with ffiD include anti-
inflammatory agents (i.e. aminosalicylates) and immune-modulators (Bousvaros & Leichtner, 
20 14). Over-the-counter medications may be needed for maintenance treatment. These agents 
will now be described. 
Aminosalicylates 
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Preparations containing 5-aminosalicylic acid (5-ASA) are formulated to release the drug 
at specific sites in the gastrointestinal tract, since efficacy is dependent on luminal concentration. 
Common agents of 5-ASA used for maintenance treatment in adolescents with IBD include 
sulfasalazine and mesalamine. These medications inhibit synthesis of pro-inflammatory 
prostaglandins and leukotrienes. If 5-ASA medications are effective in eliminating symptoms 
and avoiding frequent relapses, they are generally preferable to immune-modulators because of 
the lower toxicity. Abrupt discontinuation of 5-ASA is not recommended and may result in 
relapse (Bousvaros & Leichtner, 2014). 
The most common side effects of 5-ASA are headache, dizziness, increased sensitivity of 
skin to sunlight, itchiness, anorexia, upset stomach, nausea, vomiting, abdominal pain, cramps 
and diarrhea. Common adverse effects of 5-ASA may include haemolytic anemia and 
hepatotoxicity. Reversible oligospermia has been reported with sulfasalazine. Many of these side 
effects are dose related. They can be mild or severe, temporary or permanent (Chami & Feagan, 
2011). It is suggested that monitoring of patients with 5-ASA should include complete blood 
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counts at least twice a year, and liver function tests and urinalysis at least annually (Bousvaros & 
Leichtner, 2014). 
Immuno-modulators 
Immuno-modulators for maintenance therapy in adolescents with IBD include 
thiopurines, i.e., azathioprine (AZA) and 6-mercaptopurine (6-MP). They have been shown to be 
effective in maintaining remission because of the long onset of action. AZA is metabolized into 
6-MP and these two drugs are equally effective and differ only in their dosage. In the liver, these 
drugs are converted to 6-thioguanine nucleotides (6-TON) and 6-methylmercaptopurine 
nucleotide (6-MMPN), which inhibit lymphocyte proliferation by impairing DNA synthesis. 
Metabolite monitoring of serum levels of6-TGN and 6-MMPN can be helpful in assessing 
thiopurine metabolism, medication adherence and in optimizing drug dosing (Bousvaros & 
Leichtner, 2014). It is important to treat with appropriate dosing, as under-dosing is the most 
common cause of treatment failure in maintaining remission (Diefenbach & Bureuer, 2006). 
Side effects ofthiopurines include anorexia, nausea, GI discomfort, diarrhea and 
arthralgia. Adverse effects ofthiopurines include increased risk of opportunistic infection, bone 
marrow suppression, blood dyscrasias and rarely pancreatitis, hepatotoxicity, hypersensitivity, or 
pneumonitis (Chami & Feagan, 2011 ). These have been associated with an inherited inability to 
metabolize thiopurines. Patients with an alteration in the gene ofthiopurine methyltransferase 
(TPMT) have deficit TPMT activity and are at risk for marked elevations of the active 6-
thioguanine nucleotides which result in severe leucopenia. A screening test is available to 
determine TPMT genotype as well as thiopurine metabolism (Diefenbach & Bureuer, 2006). 
Patients treated with 6-MP or AZA require frequent monitoring for complete blood count and 
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aminotransferase levels. If patients are stable, they should be monitored every 3 months and 2 to 
3 weeks after a change in dose (Bousvaros & Leichtner, 2014). 
Over-the-Counter Medications 
Over-the-counter medications, such as vitamins, minerals and other supplements, may be 
recommended along with the above maintenance medications. They are required due to mal-
absorption following intestinal inflammation and due to the effects of maintenance medications. 
For example, since sulfasalazine competitively inhibits folate absorption, patients should be 
treated simultaneously with folate (Reed-Knight, Lewis, & Blount, 2011). Adherence to folate 
supplementation and 5-ASA maintenance therapy may reduce the risk of colon cancer 
(Bousvaros & Leichtner, 2014). 
The choice of maintenance medications and the dose of medications depend on the 
patient's disease severity and initial response to medications. Although medications for 
maintenance therapy expose patients to a number of medication-related side effects or adverse 
events, appropriate maintenance therapy throughout childhood and adolescence is required to 
prevent relapses of the disease and colorectal cancer (Zheng & Kennedy, 2009). Monitoring for 
both safety and adherence is a challenge in management ofiBD. The following section will 
define medication adherence and discuss methods for measuring adherence. 
Defining and Measuring Medication Adherence 
To improve medication adherence, FNPs need to understand how medication adherence 
is defined and measured in order to identify adolescents who are non-adherent or at risk for non-
adherence to maintenance medications. 
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Definition of Adherence and Non-adherence 
Adherence to long-term therapy is defined as the extent to which an individual's 
behaviour corresponds with a healthcare provider's recommendations, including taking 
medications, following a diet, or modifying a lifestyle (WHO, 2003). This paper is focused 
specifically on adherence to oral medications. According to the International Society for 
Pharmacoeconomics and Outcomes Research, medication adherence is defined as the extent to 
which a patient takes medication in accordance with the prescribed interval and dose (Hawthorne 
et al., 2008). 
In studies of medication adherence in adolescents with IBD, medication adherence was 
defined80% of the medications taken in the past seven days or one month in accordance with the 
prescribed interval and dose. Non-adherence was considered when medications were taken less 
than 80% in accordance with the prescribed interval and dose. To quantify adherence, the 
number of prescribed doses minus the number of missed doses is divided by the number of 
prescribed doses and multiplied by I 00 (Zelikovsky & Schast, 2008). 
In clinical settings and literature, the terms compliance and adherence are often used 
synonymously. The term compliance has fallen out of favour, because it implies that patients 
need to be obedient. Adherence has become more widely used, because it suggests that patients' 
behaviour is concordant with healthcare providers' recommendations. Moreover, patients are 
considered active partners with health professionals in their own care. Adherence reflects 
collaboration between the patient and the provider with regards to a treatment plan (Hommel, 
Greenley, Maddux, Gray, & Mackner, 2013). 
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Methods of Measuring Medication Adherence 
In the context of family practice, common methods for measuring adherence rates include 
subjective and objective assessments. Subjective assessments include patient reports via 
standardized interviews and/or questionnaires. For adolescents with IBD, both adolescent and 
parent reports of adherence are often used because of the high level of parent involvement in 
medication administration (Wu, Pai, Gray, Denson, & Hommel, 2013). Objective assessments 
include pill count, checking prescription refills, the use of electronic medication monitors and 
drug assays. 
Each method of adherence assessment has its inherent strengths and weaknesses. 
Subjective assessments are cost-effective and feasible clinic-based assessments. However, self-
reports tend to overestimate medication adherence and may be somewhat time consuming to 
administer (Hommel et al., 2009). A study of 42 adolescents with IBD by Hommel et al. (2009) 
found that non-adherence rates were 10% for 6-MP/AZA and 2% for 5-ASA using adolescent 
interviews as a subjective assessment. In contrast, non-adherence rates for these same patients 
were 64% for 6-MP/AZA and 88% for 5-ASA using objective assessments (pill count and drug 
assays). This study highlights the significant discrepancy between subjective and objective 
assessment of non-adherence, suggesting both subjective and objective methods may be required 
to effectively monitor adherence in adolescents taking maintenance medications for IBD. 
A second study that illustrates how subjective assessments overestimate adherence 
compared to objective assessments was a prospective observational study conducted by Gifford, 
Berg, Lahiff, Cheifetz, Horowitz and Moss (2012) in 93 patients with UC taking mesalamine for 
maintenance therapy. A random urine salicylate level above 15 mgldL distinguished patients 
who had recently taken mesalamine from controls. The researchers found that approximately 
one-third of patients who self-identified as "high adherers" by an adherence questionnaire had 
random levels of urine salicylates below the threshold of 15 mg/dL. This study again identifies 
that subjective assessments can overestimate medication adherence. 
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Compared to subjective assessments, objective methods can provide more reliability but 
also have drawbacks. Data from pill count, checking prescription refills and use of electronic 
medication monitors are based on the assumption that patients do not discard their medications, 
for example, adolescents do not discard medications that are to be taken during school hours. 
These data cannot confirm actual medication ingestion or whether the appropriate number of 
pills was taken. Electronic medication monitoring devices can malfunction, as they contain an 
integral electronic microcircuit that records the time and date of each opening and closing of the 
container. Another drawback is they are expensive and may not be available in all primary care 
settings (Leleiko et al., 2013). 
Bioassays are also an objective measure of drug metabolites in blood or urine, but they 
can be affected by individual pharmacokinetics and are subject to bias due to white coat 
compliance, i.e., adolescents more conscientiously taking medications prior to medical 
appointments (Wu et al., 2013). Metabolite monitoring of serum levels of6-TGN and 6-MMPN 
can be helpful in assessing medication adherence in patients treated with 6-MP/AZA. Measuring 
serum levels of 5-ASA as well as its metabolites in urine can be useful in assessing medication 
adherence, and is practical for routine use in clinic settings. Patients taking 5-ASA excrete a 
proportion of the ingested dose as 5-ASA or n-acetyl-5-ASA in the urine, which can be detected 
and quantified within 4 hours after an ingested dose and remains detectable for up to 5 days after 
discontinuation. Random urine screening for a salicylate level provides a better indication of 
medication adherence to 5-ASA (Gifford et al., 2012). 
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Both subjective and objective measures offer unique data for assessing medication 
adherence. The discrepancy between subjective and objective assessments of adherence and the 
drawbacks of each method underscore the importance of multiple methods for adherence 
assessment. Application of multiple methods to assess adherence is current practice, as it may 
provide more reliable and realistic adherence estimates (Hommel, Herzer, Ingerski, Rente & 
Denson, 2011). 
The Significance of Promoting Medication Adherence 
Adherence to medications throughout the maintenance phase is central to maintaining 
remission. Addressing medication adherence should be considered a major component in 
managing patients with IBD (Kane et al., 2012). The need for promoting medication adherence 
in adolescents with IBD is important for several reasons, including preventing relapses, 
complications and morbidities, improving physical and psychosocial wellbeing and reducing 
healthcare costs. 
Preventing Relapses, Complications and Morbidities 
Non-adherence to maintenance medications has significant consequences on relapses of 
IBD, disease activity, complications and morbidities (Hawthorne et al., 2008). No studies were 
found to report the impacts of non-adherence to maintenance medications on disease activity, 
complications and morbidities in adolescents with IBD. In adult patients with quiescent UC, non-
adherence to 5-ASA resulted in relapse in 61% of patients over 2 years, whereas only 11% of 
adherent patients experienced relapses. Only about 40% of patients on 5-ASA were fully 
adherent to maintenance therapy. Relapse rates over 2 years are significantly higher in non-
adherent patients with UC (Kane et al., 2003). 
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Non-adherence or disruption of maintenance therapy destabilizes disease activity, leading 
to exacerbations of symptoms, such as nausea, abdominal pain, fatigue, diarrhea, fistulae or 
abscesses (Robinson, Hankins, Wiseman, & Jones, 2013). In the long term, adherence to 
maintenance medications significantly reduces the risk of developing colorectal cancer by up to 
75% in UC patients (Van et al., 2005). 
Improving Physical and Psychosocial Wellbeing 
Growth failure in adolescents with IBD can be reversed if the disease is controlled 
medically, use of maintenance therapy is maximized, and sufficient dietary energy and nutrients 
are provided (Bousvaros & Leichtner, 2014). Adolescents with non-adherence are more likely to 
experience poorer overall quality of life in physical, emotional, social and school areas, and have 
greater anxiety and depressive symptoms (Gray et al., 2012; Hommel, Davis, & Baldassano, 
2008). Achieving disease remission results in significant improvement of bowel symptoms, but 
also overall physical and psychosocial wellbeing. Exacerbations of clinical symptoms can be a 
source of psychological issues in adolescents (Robinson et al., 2013). 
Reducing Healthcare Costs 
Non-adherence to maintenance medications contributes to the high costs associated with 
treatment of relapses of IBD. Adolescents who are not adherent are more likely to have greater 
disease severity, potentiating the need for more aggressive and costly medical treatment (Gray et 
al., 2012). Poor adherence poses the risk of increasing dosages to toxic levels or needlessly or 
prematurely stepping up therapy, when what is actually needed is better adherence to the original 
treatment regime (Leleiko et al., 2013). Although there is no data available pertinent to an 
adolescent population, there is evidence that for adults with IBD, disease relapses are associated 
with a two or three fold increase in costs for non-hospitalized cases and a 20-fold increase in 
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costs for hospitalized cases compared with quiescent cases of IBD (Bassi, Dodd, Williamson, & 
Bodger, 2004). 
Given that non-adherence rates for maintenance medications in adolescentswith IBD 
range from 50% to 88% (Hommel et al., 2009; Mackner & Crandall, 2005; Oliva-Hemker at al., 
2007) and its considerable impacts on health outcomes and healthcare costs, it is important for 
healthcare providers to understand the factors affecting adherence in adolescents with IBD and to 
develop and implement intervention strategies to promote medication adherence. 
In primary care settings, FNPs not only diagnose and manage medical issues; they also 
focus on the effects of illness on the life of individual patients and families, and emphasize 
health promotion, patient education/counselling and disease prevention (College of Registered 
Nurses ofBritish Columbia, [CRNBC], 2012). According to the scope of practice ofFNPs in 
BC, FNPs cannot initiate IBD treatment and maintenance medications or continue prescribing 
immune-modulators. But, they can continue prescribing 5-ASA agents, such as sulfasalazine. 
FNPs are involved in the continuity of care for patients of all ages with IBD and are responsible 
for monitoring maintenance therapy and assessing adherence as part of the team providing care. 
Therefore, FNPs need to understand maintenance therapy for IBD, factors affecting adherence 
and intervention strategies that can be used to improve adherence as needed. 
The Bio-psychosocial Model 
The bio-psychosocial (BPS) model was originally described by Engel (1980). Engel 
suggested that healthcare professionals move beyond the biomedical model to gain a 
comprehensive understanding of the aetiology and progression of disease; the interactions 
between physical and psychosocial variables must be examined in order to successfully provide 
effective care of patient health and wellbeing. This bio-psychosocial perspective provides a 
comprehensive approach to examine the issue of non-adherence in adolescents with IBD. 
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Adolescents with ffiD have a greater vulnerability with physical, social and 
psychological issues. In adolescence, there are a number of developmental milestones, such as a 
greater desire for autonomy, more need and interest in activities with peers rather than with 
family and an increased awareness of fitting in with peers. These normative transformations 
challenge adolescents to adhere to maintenance medications of IBD (Hommel, Greenley et al., 
2013). Adolescents with ffiD often express frustration and anger about the unpredictable disease 
activity, energy levels, body image and decreased physical and social activities. They are more 
vulnerable to psychosocial issues than healthy peers, due to disturbing symptoms, altered 
physical appearance, invasive medical procedures or surgical interventions. This may influence 
their overall adjustment and coping strategies (Mamula et al., 2003). 
Examining the issue of non-adherence with a bio-psychosocial perspective facilitates the 
identification of the psychosocial issues associated with the disease and medication adherence. 
Many adolescents with IBD have fears about how the disease will affect their future school and 
employment, as well as the long-term side effects of medications. Feelings ofhelplessness, 
dependency and low self-esteem, anxiety and depressive symptoms can have direct implications 
on adherence to treatment plans (Mackner & Crandall, 2006). Because these issues are 
associated with poor adherence, it has been suggested that psychotherapy addressing these areas 
may contribute to improved medication adherence (Mackner & Crandall, 2005). Given the 
significance of psychosocial issues associated with the disease and medication adherence among 
adolescents with ffiD, examination of non-adherence is likely best conceptualized with the BPS 
model. 
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Using the BPS model to explore the role ofFNPs in promoting medication adherence 
also fits with the philosophy of primary health care (PH C). A PHC model embraces five types of 
care, namely promotive, preventative, curative, rehabilitative, supportive and palliative 
(Canadian Nurses Association [CNA], 2000). Health promotion and disease prevention are an 
element of the PHC approach and are integrated in FNP practice in primary care settings. In 
contrast, a primary care model, or a biomedical model, is largely medical-centered and illness-
oriented (CNA, 2000). The BPS model integrates the biomedical and psychosocial perspectives 
and emphasizes the roles of psychosocial variables in disease progression, health promotion and 
illness prevention. Application of the BPS model enables healthcare providers to examine the 
biological, psychological and social variables in relation to non-adherence and to provide 
promotive, preventative and supportive care of adolescents and their families. 
Biomedical solutions, when applied without attention to psychosocial issues, are not 
likely to maximize adherence that can be provided in a BPS approach (Leleiko et al., 2013). It is 
for these reasons that the BPS model was chosen as a conceptual framework to examine the 
literature and analyze the review in this paper. IfFNPs have knowledge of the disease processes, 
treatment goals and regimens, tools for assessing medication adherence, and employ a BPS 
approach to medication adherence, they are well prepared to understand the complexities of 
factors affecting medication adherence and plan intervention strategies in a relevant and 
appropriate manner to improve medication adherence. To explore factors affecting adherence 
and intervention strategies for improving medication adherence, a literature search was 
conducted and will be presented in the next chapter. 
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Chapter Two: Literature Search Strategy 
This paper aims to provide intervention strategies for improving medication adherence in 
adolescents with illD. This literature review was guided by two research questions: 1) in 
adolescents with illD, what factors affect their adherence to oral medications for maintenance 
treatment? 2) What are intervention strategies that FNPs can use to improve oral medication 
adherence in adolescents with illD? This chapter will summarize the search methods and the 
articles retrieved for conducting an integrative literature review. 
Literature Search Methods 
The literature search was conducted using the electronic online databases through the 
University ofNorthem British Columbia and Interior Health Authority libraries. The search 
terms or key words were based on the research questions and were combined variously using 
"AND" or "OR" (see Box 1). A search realm was defined in medicine, nursing, pharmacology 
and psychology. Electronic databases include Medline, CINAHL, Psyclnfo, Cochrane and 
Google Scholar. Additionally, reference lists of review papers were hand searched for applicable 
papers. The website ofCrohn's and Colitis Canada was also included. 
Box 1. Search terms for Medline, CINAHL, PsyciNFO, Cochraneand Google Scholar 
inflammatory bowel disease OR ulcerative colitis OR Crohn's disease OR Crohn* 
AND 
adhere* OR complian* OR concordanc* OR non-adheren* OR non-complian* 
AND 
medication OR treatment OR therapy OR interven* OR strateg* 
AND 
adolescen* OR paediatric OR teenager 
Limits: from the year 2000 onward. 
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The collection of relevant literature followed three steps. First, literature was initially 
selected by screening the titles of the articles. Second, literature was sampled by reviewing the 
abstracts of the articles. The inclusion criteria for keeping abstracts were based on their relevance 
to the topic of the project (see Box 2). Third, literature was collected by examining the full texts 
of primary research articles, review articles and clinical reports. The full texts of articles were 
retrieved based on the inclusion (see Box 3) and exclusion criteria (see Box 4). Preliminary 
literature review had suggested that medication adherence started to become a major topic of 
interest around 2000. Therefore, 2000 was chosen as the starting point for this literature search. 
Box 2. Inclusion criteria for keeping abstracts 
• Published in English 
• Adolescents with ffiD (10-19 years old according to WHO). 
• Adherence to oral medications (including supplements) 
• Maintenance therapy 
• Rates/impacts of non-adherence. 
• Methods of measuring adherence. 
• Factors affecting non-adherence to maintenance medication. 
• Interventions/strategies for improving medication adherence. 
• Published from the year 2000 onward 
Box 3. Inclusion criteria for keeping full texts of articles 
The inclusion criteria for keeping abstracts and plus: 
• Original research articles 
• Qualitative, quantitative or mixed studies 
• Clinical reports and review articles 
• Peer-reviewed journal articles 
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Box 4. Exclusion criteria for keeping full texts of articles 
• Literature not in English 
• Published before the year 2000 
• Non journal articles 
Articles Retrieved 
A combination of different search terms yielded 64 articles in the selected electronic 
databases. Forty articles were kept after screening the titles of articles. After reviewing the 
abstracts of articles, 31 articles were kept based on the inclusion criteria. A total of 20 articles 
with full texts were kept after reviewing the full texts of articles, including 12 articles on factors 
affecting medication adherence and 8 articles on intervention strategies. The number of articles 
included and excluded at each step is presented in Box 5. The number and the themes of final 
articles reviewed are presented in Box 6. 
Of note, the literature review was carried out in two sections: factors affecting non-
adherence using the 12 articles (see Chapter three) and intervention strategies for improving 
medication adherence using the 8 articles (see Chapter four). A paucity ofliterature was found 
for intervention strategies in adolescents with mo. Of the 8 articles, 4 studies were conducted in 
adolescents between the ages 11 and 18 years, 4 other studies that included both adolescents and 
adults were also included, because these 4 studies included older adolescents between the ages of 
17 and 19 years and provided a value-added source of intervention strategies for improving 
medication adherence. 
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Box 5. Numbers of the articles included and excluded at each step 
Articles yielded with combination of different search terms cross 64 
databases and reference search 
Articles yielded after screening the titles Included: 40 Excluded: 24 
Articles yielded after reviewing the abstracts Included: 31 Excluded: 9 
Articles with full texts retrieved that met the inclusion criteria Included: 20 Excluded: 11 
Box 6. Numbers and themes of the articles retrieved with full texts 
Numbers ofthe articles (total20) Themes of the articles 
12 original studies factors affecting medication adherence 
8 original studies intervention strategies for improving medication adherence 
Chapter Three: Factors Affecting Medication Adherence 
Identifying the factors that affect medication adherence is a first step in targeting 
interventions to improve medication adherence (Kane & Robinson, 2010). For this purpose, 
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twelve studies were retrieved and reviewed to answer the first research question: "In adolescents 
with IBD, what factors affect their adherence to oral medications for maintenance treatment?" 
Before delving deeper into understanding the factors affecting medication adherence, tools used 
in the literature to identify factors will be briefly introduced in the following section. 
Assessment Tools to Identify Factors Affecting Adherence 
Common tools employed in literature to identify factors affecting adherence are 
presented in Box 7, and are described later, including tools for assessing knowledge, behavioural 
factors, psychosocial issues, family functioning and coping strategies. 
Box 7. Common tools to identify factors affecting medication adherence 
Assessing knowledge and behavioural factors 
The Medication Adherence Measure (MAM) 
The Medication Adherence Interview (MAl} 
The Treatment Adherence Interview (TAl) 
Assessing family functioning 
The Family Assessment Device (FAD) 
IBD Family Responsibility Questionnaire (IBD-
FRQ) 
The Issue Checklist 
Assessing psychosocial issues 
The Child Behavioural Checklist (CBCL) 
The Youth Self-Report (YSR) 
The Children's Depression Inventory (CDI) 
The Multidimensional Anxiety Scale for 
Children (MASC-2) 
The Medication Adherence Interview (MAl) 
Assessing coping strategies 
The Coping Strategies Inventory (CSI) 
The Piers Harris Self-Concept Scale 
(PHSCS) 
Tools for Assessing Knowledge and Behavioural Factors 
The Medical Adherence Measure (MAM}, the Medication Adherence Interview (MAl) 
and the Treatment Adherence Interview (TAl} were commonly used to assess knowledge of 
treatment and medication regimens and behavioural factors affecting adherence. 
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The MAM is a validated and reliable semi-structured interview administered during 
standard clinical care (validity 0.40 and reliability 0.89). The MAM contains 12 commonly 
identified barriers to medication adherence. Respondents answer yes, if they perceive each item 
to be a barrier to adherence. This tool also asks respondents to report the number of doses of 
medication they have missed in the past 7 days (Zelikovsky & Schast, 2008). With its two fold 
purposes, i.e. measuring medication adherence and assessing barriers to adherence, the MAM 
was used in seven studies (see Table 1 ). It was conducted jointly or separately with adolescents 
and their parents, based on the aims of the clinician, patient population, or purpose of research. 
The MAl designed by Mackner and Crandall (2005) is a semi-structured interview for 
assessing barriers to adherence in children with IBD. These factors include educational 
(knowledge of treatment and medications, etc.}, organizational (placement of medication in 
house, who refills pill organizer, etc.), behavioural (refusal to take medications) and emotional 
(anxiety and depressive symptoms) domains. The T AI was modeled after the MAl by Hommel 
and Baldassano (2010). It only contains eight questions and was used during a routine clinic visit 
in two studies (Hommel & Baldassano, 2010; Hommel, Odell, Sander, Baldassano, & Barg, 
2011). 
There has been no report about reliability or validity of the MAl and TAL However, they 
were specifically used to assess barriers to adherence in children with IBD. The interview 
questions were well designed with input from a psychologist, gastroenterologist and 
anthropologist representing expertise in paediatric behavioural medicine and medication 
adherence. 
Tools for Assessing Psychosocial Issues 
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The Child Behavioural Check List (CBCL), the Youth Self-Report (YSR), the Children's 
Depression Inventory (CD I), the Multidimensional Anxiety Scale for Children (MASC-2) and 
the MAl were commonly used in the studies for assessing psychosocial issues. 
The CBCL is a validated and reliable measure used to assess a range of behavioural and 
psychosocial problems of children aged 6 to 18 years. It contains 113 items that yield 8 factors: 
aggressive behaviour, anxious/depressed, attention problems, rule-breaking behaviour, social 
problems, somatic complaints, thought problems and withdrawal (Achenbach & Rescorla, 2001). 
The YSR is a version of the CBCL, but for use only with children 11 years and older. Both tools 
have been found to be reliable (test-retest reliability from 0.70 to 0.74) and valid (internal 
consistency from 0.82 to 0.96). The child or adolescent completes the YSR, whereas parents 
complete the CBCL (Achenbach & Rescorla, 2001). 
The CDI is a 27-item self-report measure widely used to assess the severity of depression 
and/or dysthymic disorder in children and adolescents aged 7 to 17 years. The CDI has been 
found to be reliable (internal consistency for the total score a=0.86) (Finch, Saylor, Edwards, & 
Mcintosh, 1987). The MASC-2 is a comprehensive assessment of anxiety dimensions in children 
and adolescents aged 8 to 19 years, including physical symptoms, harm avoidance, social anxiety 
and separation/panic. The MASC-2 has been found to be reliable (internal consistency a from 
0.73 to 0.89 for child report and from 0.7 to 0.9 for parent report) (Baldwin & Dadds, 2007). 
Tools for Assessing Family Functioning 
The Family Assessment Device (FAD) and IBD Family Responsibility Questionnaire 
(IBD-FRQ) and the Issues Checklist were commonly used in the studies for assessing family 
functioning. 
The FAD contains 60 questions used to evaluate family functioning in seven areas: 
problem solving, communication, roles, emotional responsiveness, emotional involvement, 
behavioural control and general functioning. These questions are completed by all family 
members over the age of 12. The FAD has been found to be reliable and valid. The internal 
consistency (a) for the subscale ranged from 0.93 to 0.90, predictive validity r = 0.47 (Miller, 
Epstein, Bishop, & Keitner, 1985). 
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The IBD-FRQ is a measure of adolescent and parental involvement in IBD management. 
It contains 26 items and includes adolescent, maternal and paternal report forms. IBD-FRQ has 
been found to be reliable. Internal consistency estimates for adolescent and parent report were 
good with a ~0.88 and a~ 0.92, respectively (Greenley, Doughty, Stephens, & Kugathasan, 
2010). 
The Issues Checklist is a scale containing a list of 44 issues that can lead disagreements 
between parents and adolescents. It can be assessed with adolescent and parent reports regarding 
the frequency and common sources of conflicts between the adolescent and parents during the 
previous two weeks. Internal consistency estimates were good with a = 0.68 for adolescent 
report of conflict frequency and a= 0.89 for parent report of conflict frequency (Greenley, 
Doughty et al., 201 0). 
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Tools for Assessing Coping Strategies 
The Coping Strategies Inventory (CSI) and the Piers Harris Self-Concept Scale (PHSCS) 
were used in studies for assessing coping strategies. The CSI was to assess coping thoughts and 
behaviours that children and adolescents use to deal with stressful situations during the past 
month. It is a 72-item self-report questionnaire and contains 8 primary subscale items, including 
problem solving, cognitive restructuring, social support, express emotions, problem avoidance, 
wishful thinking and social withdrawal subscales. The internal consistency (a) for the subscales 
ranged from 0.71 to 0.94 {Tobin, 2001). 
The PHSCS was designed by Piers to assess self-esteem in children between the ages of 7 
and 18 years. The scale yields a general measure ofthe respondent's overall self-concept, and 
includes six domain subscales including behavioural adjustment, intellectual and school status, 
physical appearance, attitudes, freedom from anxiety and happiness and satisfaction. This 
measure is widely used in both schools and clinical settings to determine specific areas of 
conflict, typical coping and defence mechanisms and appropriate intervention techniques. This 
scale was found to be reliable. The internal consistency (a) for the subscales ranged from 0.88 to 
0.93 (Alexopoulos & Foudoulaki, 2002). 
In summary, among these tools for assessing factors affecting adherence, the MAl, the 
TAl and the mD-FRQ were designed specifically to assess specific barriers to adherence in 
children with mo. The other assessment tools were not developed specifically for mo patients, 
but are commonly used to assess knowledge and behavioural factors, psychosocial issues, family 
functioning and coping strategies in children and families, Understanding these tools will help 
FNPs to identify specific factors affecting adherence in adolescents with mo. 
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Factors Affecting Medication Adherence 
A literature matrix was created to analyze the twelve studies reviewed, including the 
above methods for measuring medication adherence and the tools for assessing factors affecting 
adherence (See Table 1 ). Literature revealed that factors affecting adherence included disease 
and medication-related factors, psychosocial and behavioural issues and knowledge and health 
beliefs about treatment and medications. These factors will be presented in the following section. 
Disease and Medication-Related Factors 
Four quantitative studies identified that non-adherence was related to disease activity and 
treatment regimens, such as patient being asymptomatic in remission (when they. felt well so they 
might not take medications regularly), complex medication regimens (multiple daily doses and 
number of pills per dose), medication side effects(headache, nausea or diarrhea), or difficulty 
swallowing pills due to the size and taste ofpills(Gray et al., 2012; Greenley, Stephens, Doughty, 
Raboin, & Kugathasan, 2010; Hommel & Baldassano, 2010; Hommel, Denson et al., 2011). 
Greenley, Stephens et al. (2010) conducted a study to examine demographic, disease-
related and treatment regimen-related factors for adherence in 64 adolescents (11-18 years old) 
with ffiD. The goal of this study was to investigate relationships between the frequencies of 
barriers and levels of non-adherence. Barriers to adherence and medication adherence rates were 
assessed via patient and parent reports with the Medication Adherence Questionnaire. This study 
revealed that concerns about medication side effects and multiple daily doses of medications 
were common adherence barriers reported by adolescents and parents. Approximately 14% of 
adolescents and 19% of their parents reported concerns about medication side effects. 
Adolescents whose regimen involved more than one daily medication administration reported 
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having more barriers to adherence. Adolescents also reported discontinuing medication was due 
to feeling well. 
The prevalence of adherence barriers in this study was not significantly associated with 
adolescent age, gender and time since diagnosis (in months). Findings of this study could be 
affected by limitations, such as use of cross-sectional data, homogeneous characteristics of 
participants and a small sample size (Greenley, Stephens et al., 201 0). 
Three other studies reported that along with complex treatment regimens and medication 
side effects, large pill sizes, difficulty swallowing pills and the unpleasant taste of pills were 
reported by adolescents to be barriers to adherence (Gray et al., 2012; Hommel & Baldassano, 
2010; Hommel, Denson et al., 2011). These three studies will be discussed further in the sections 
on psychological/psychosocial and behavioural factors. 
In addition to the above factors affecting medication adherence, the association between 
non-adherence and disease duration was also examined. Non-adherence was found to be 
associated with longer disease duration in two studies (K.itney et al., 2009; Reed-Knight et al., 
2011). However, the prevalence of adherence barriers was not significantly associated with time 
since diagnosis (Greenley, Stephens et al., 2010). 
Psychosocial Factors 
The literature identified that psychosocial factors in the adolescents themselves as well as 
in their families affected medication adherence. Psychosocial factors such as anxiety and 
depressive symptoms, helplessness, dependency and low self-esteem were associated with non-
adherence in adolescents with IBD (Gray et al., 2012; Hommel, Denson, et al., 2011; Leleiko et 
al., 20 13; Mackner & Crandall, 2005). Family psychosocial distress was related to non-
adherence in adolescents in the forms of parent-child conflicts, family dysfunction, poor coping 
strategies and less parental involvement (Hommel, Odell et al., 2011; Mackner & Crandall, 
2005; Reed-Knight et al., 2011). 
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Psychosocial issues in adolescents. In four studies, non-adherence in adolescents with 
ffiD was found to be related to anxiety and depressive symptoms, helplessness, dependency and 
low self-esteem in adolescents (Gray et al., 2012; Hommel, Denson, et al., 2011; Leleiko et al., 
2013; Mackner & Crandall, 2005). 
Gray et al. (2012) examined the collective impact of barriers to adherence and 
anxiety/depressive symptoms on medication adherence in 79 adolescents with ffiD. Barriers to 
adherence were assessed with the Medical Adherence Measure (MAM) and psychological 
functioning was assessed with the Child Behaviour Check List (CBCL). Results revealed that 
one in eight adolescents reported borderline or clinically elevated levels of anxiety/depressive 
symptoms. Anxiety/depressive symptoms had a negative additive impact on behavioural factors 
for adherence. Forgetfulness, being away from home and interference with activities were the 
mostly commonly reported behavioural barriers to adherence (Gray et al., 2012). 
This study used multi-site data collection, which allows for the recruitment of a sample 
larger than typically included in paediatric ffiD research. But findings might be affected by 
limitations, such as the cross-sectional nature of data, the relatively homogeneous sample and the 
use of self-report for adherence assessment (Gray et al., 2012). 
Mackner and Crandall (2005) examined factors associated with poor adherence in 50 
children with ffiD 11-17 years of age and their parents. Patients and parents were interviewed 
separately with the Medication Adherence Interview. Personnel who did not provide direct 
medical care conducted the interviews. Self-esteem was assessed in intellectual and school 
status, physical appearance, popularity and behaviour. Coping strategies were assessed with a 
range of thoughts and behaviours that adolescents used to deal with stressful situations. 
Problems/emotional problems were assessed with the CBCL and the Children's Depression 
Inventory (CDI). 
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This study revealed that disease-associated psychosocial distress and vulnerability, such 
as helplessness, dependency and low self-esteem, were identified as impediments for adherence 
in adolescents. There was a significant correlation between more behavioural and/or emotional 
problems and lower adherence (Mackner & Crandall, 2005). Although data were obtained from 
adolescent and parent reports, the authors used well-structured and validated assessment tools. 
Moreover, findings were improved with parent-child concordance, as personnel who did not 
provide direct medical care conducted interviews with parents and children separately. 
Hommel, Denson et al. (2011) and Leleiko et al. (2013) investigated the association 
between behavioural and emotional problems and medication adherence. Both studies suggested 
that psychosocial functioning, anxiety and depressive symptoms, especially among older 
adolescents, substantially contributed to non-adherence. Medication adherence was assessed with 
different methods in these two studies. Subjective method with the MAM (adolescent and parent 
reports) was used in Hommel, Denson et al. (2011), while objective method with electronic 
medication monitoring device was used in Le1eiko et al. (2013). 
In Hommel, Denson et al. (2011), the relationship of barriers to adherence and adolescent 
behavioural functioning and psychosocial distress was examined in 62 adolescents with 5-ASA 
and/or 6-MP/AZA. Barriers to adherence were assessed with the MAM, using adolescent and 
parent reports. Psychosocial distress and psychological functioning were assessed with the 
CBCL and the CDI (adolescents and parents completed questionnaires). Results revealed that 
15% of adolescents reported clinically elevated depressive symptoms and 24% reported 
clinically elevated internalizing behavioural problems. Increased incidence of clinically 
significant emotional problems, particularly depression, was found to be associated with a 
greater number of reported barriers to adherence. 
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The findings from this study may be limited by a small sample size and homogeneous 
characteristics of participants. The majority of families in this study did not represent families of 
various socio-economic backgrounds, but of upper middle socio-economic class. The subjective 
assessment of adherence may have resulted in overestimates of adherence (Hommel, Denson et 
al., 2011). 
In Leleiko et al. (2013), whether behavioural and emotional problems predicted non-
adherence to maintenance medications was investigated in 79 adolescents. Psychosocial distress 
and psychological functioning were assessed with the CBCL and the CDI (adolescents and 
parents completed questionnaires). Results revealed that adolescents aged 15 or older had 
significantly lower adherence rates. Anxiety and depressive symptoms, especially among older 
adolescents, significantly contributed to non-adherence. A limitation to this study is that 
medication adherence rates derived from the electronic medication monitoring device may 
represent an overestimate of adherence, as this device can only document the times that it was 
opened, but not the actual ingestion (Leleiko et al., 2013). 
Psychosocial issues in families. In three studies, non-adherence to maintenance 
medications was identified related to psychosocial distress in families, including parent-child 
conflicts, family dysfunction and less maternal involvement (Hommel, Odell et al., 20 ll; 
Mackner & Crandall, 2005; Reed-Knight et al., 2011). 
As discussed previously, Mackner and Crandall (2005) highlighted correlation between 
emotional/behavioural problems and lower adherence. In particular, this study identified that 
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family functioning was a key dynamic affecting adherence. Parent-child concordance in reports 
of adherence was also examined in this study. Family functioning was assessed in the areas of 
problem solving, communication, roles and emotional and behavioural control. Coping strategies 
were assessed using the range of thoughts and behaviours that adolescents used to deal with 
stressful situations. Results revealed that poorer adherence was associated with family 
dysfunction, which included characteristics such as poor family structure, a lack of cohesion and 
child discipline. Better family functioning and child coping strategies were significantly 
correlated with medication adherence. Specifically, families with appropriate rules and 
consequences for behaviours had children who were more adherent. This suggests adherence 
should be monitored in families that lack appropriate child discipline (Mackner & Crandall, 
2005). 
Hommel, Odell et al. (2011) and Reed-Knight et al. (2011) both found parent-child 
conflicts were associated with non-adherence. However, these two studies had different foci. 
Hommel, Odell et al. (20 11) used a qualitative individual interview approach to 16 adolescents 
and their parents. Parent-child dyads identified parent-child conflicts and oppositional 
behaviours as barriers to adherence. Despite the richness and diversity of the qualitative data 
obtained, the sample size was fairly modest (n= 16). Parents and adolescents were interviewed 
together in order to encourage identification and discussion of different perspectives. While this 
is a substantial advantage, an important disadvantage of this approach is the potential to have 
adolescents defer answers and opinions to their parents and this approach may have inhibited 
some responses by both participants. In addition, this study was conducted during regular 
scheduled clinic visits, which makes prolonged interviews unfeasible. 
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Reed-Knight et al. (2011) used quantitative data to examine factors associated with 
adherence to both prescription and over-the-counter (OTC) medications. This study revealed that 
a lack of autonomous motivation, less maternal involvement and more perceived parent-child 
conflicts were associated with poor adherence to both prescription and OTC medications. Parents 
who perceived more conflicts in their relationship with their adolescents were less likely to 
promote adherence to avoid another conflict. Despite several limitations in this study, such as 
adolescent and parent reports of adherence, cross-sectional data and a homogeneous sample, the 
results are an important addition to the literature on adherence in adolescents with IBD. 
Psychosocial factors affecting medication adherence summarized from the above studies 
included anxiety and depressive symptoms, disease-associated psychosocial distress and 
vulnerability such as helplessness, dependency and low self-esteem of adolescents, family 
dysfunction, parent-child conflicts and less maternal involvement. Psychosocial issues in both 
adolescents and families correlated with behavioural issues of adolescents contributing to non-
adherence to IBD treatment (Mackner & Crandall, 2005). 
Behavioural Factors 
In five studies, forgetfulness was identified as the most common factor affecting 
adherence, followed by interference with activities, not being home and medications not being 
refilled (Gray et al., 2012; Hommel & Baldassano, 2010; Hommel, Denson et al., 2011; 
Hommel, Odell et al., 2011; Ingerski, Baldasano, Denson, & Hommel, 2010). In addition, non-
adherence was found associated with behavioural function specific to levels of attention and 
conduct problems (Reed-Knight, Lewis, & Blount, 2013). 
A study using both qualitative and quantitative data was conducted by Hommel and 
Baldassano (2010). The purpose of the study was to examine adolescents' and their parents' 
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perceived barriers to medication adherence and the relationship between non-adherence rates to 
perceived barriers to adherence. Sixteen adolescents with IBD and their parents participated in an 
open-ended interview regarding barriers to adherence using the MAM. Medication adherence 
was assessed with a combined method including self-reports and pill counts. The most 
commonly identified barriers to adherence were forgetfulness, interference with activities and 
not being home. Non-adherence frequency was 42% for 6-MP/AZA and 50% for 5-ASA. This 
study also revealed the significant correlation between non-adherence rates and perceived 
barriers to adherence by adolescents and their parents. 
This is the only study using qualitative and quantitative data to examine barriers to 
adherence and the frequency of non-adherence to maintenance medications. Using mixed 
methods, i.e. forced choice and semi-structured, open-ended interview approach to identify 
factors affecting medication adherence, and a combined measurement of assessing adherence, 
make this study outstanding from other studies. However, responses to interview questions might 
have been inhibited, when adolescents and their parents were interviewed jointly. The findings 
are limited by the small sample size (n= 16) and homogenous sample (primary Caucasian and 
fairly high annual incomes of the families). Therefore, generalization of these fmdings to ethnic 
minorities or individuals with lower annual incomes is limited. 
Using the same participants in the study by Hommel and Baldassano (2010), Hommel, 
Odell et al. (2011) conducted an extensive qualitative study to examine factors affecting 
adherence perceived by 16 adolescents and their parents. The authors administered a qualitative 
individual interview during a clinic appointment, using open-ended, semi-structured questions of 
the TAl to elicit discussion by adolescents and parents. Adolescents and parents identified 
forgetfulness, interference with activities, parent-child conflicts, oppositional behaviours and 
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inadequate planning for medications as major factors affecting adherence. Other factors affecting 
adherence included poor understanding of the purpose of medications, regimen complexity, 
embarrassment about taking medications around peers and financial and work/school issues 
(Hommel, Odell et al., 2011 ). 
This qualitative study also identified factors that could facilitate medication adherence, 
including family support, good parent-child relationships, calm discussion of non-adherence 
when it occurs, establishing a routine of taking medications, parental monitoring and reminders, 
keeping medications accessible and in the same location, using a pillbox, planning for 
medication-taking and perceived benefits of taking medications (Hommel, Odell et al., 2011). 
The two studies ofHommel and Baldassano (2010) and Hommel, Odell et al. (2011) have 
several limitations, such as small sample size (n= 16) and homogeneous characteristics of 
participants. Moreover, the interviews were conducted jointly in adolescents and their parents 
during regularly scheduled clinic appointments, which make prolonged interviews and detailed 
qualitative data collection unfeasible. 
Behavioural function specific to attention and conduct problems was examined in relation 
to non-adherence in a study by Reed-Knight et al. (2013). The purpose of this study was to 
identify the associations between attention and conduct problems, perceived barriers to 
adherence and adherence to maintenance medications in 85 adolescents with IBD. This study 
used the validated Externalizing Clinical Scales to measure attention and conduct problems and 
the MAM to assess barriers to adherence. Adolescents with known attention deficit hyperactivity 
disorder or oppositional defiant disorder were excluded from the study sample. Results revealed 
that the majority of participants reported normative levels of attention and conduct problems. 
Attention problems and conduct symptoms (e.g., rule breaking, lying, oppositional behaviours 
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and low motivation) were associated with high levels of barriers and poorer medication 
adherence. High levels of attention and conduct problems were found to interfere with 
behaviours contributing to non- adherence, such as forgetfulness and poor organization and plan 
(Reed-Knight et al., 2013). 
These findings were reported by parents but not by adolescents, suggesting that parents 
are more adept at recognizing behavioural problems and barriers that their children experienced, 
or that adolescents are less willing to acknowledge barriers. This is the only study examining the 
effects of attention and conduct problems on adherence in adolescents with IBD. Findings 
suggest that addressing attention or conduct problems in adolescents may be an effective 
intervention for promoting adherence. However, study limitations should be considered while 
interpreting and generalizing these fmdings, such as a subjective method of assessing adherence, 
homogeneous sample and the cross-sectional data. 
Ingerski et al. (20 1 0) conducted a study to identify family-reported adherence barriers to 
5-ASA and 6-MP/AZA in 74 adolescents and their caregivers. Factors for medication adherence 
were assessed with the MAM, adherence rates were assessed with pill counts and serum assays 
of 6-MP/ AZA. Adolescents and their caregivers jointly completed adherence barriers with the 
MAM. Results revealed that demographic variables were not related to adherence barriers. The 
most commonly reported barriers included forgetfulness, being away from home and interference 
with activities. Most families experienced at least one barrier to medication adherence. 
Significant correlations were found between total number of barriers and adherence. Fewer total 
numbers ofbarriers were related to better adherence. Strengths of this study include multi-site 
data collection, multiple methods of adherence assessment and inclusion of both adolescents and 
their caregivers. However, fmdings may be limited with cross-sectional and quantitative data. 
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Key behavioural factors for adherence summarized from the above four studies included 
forgetfulness, interference with activities, not being home, medications not being refilled and 
attention and conduct problems. Non-adherence is not only limited to behavioural problems, but 
also related to knowledge or concerns about maintenance treatment. Even when forgetfulness is 
the reason for non-adherence, knowledge and beliefs about maintenance treatment should be 
assessed. 
Factors related to Knowledge and Beliefs 
Five quantitative studies revealed that non-adherence was associated with a lack of 
knowledge about ffiD treatment and medications, and beliefs that treatment was not necessary or 
medications were ineffective (Gray et al., 2012; Greenley, Stephens et al., 2013; Hommel, 
Denson et al., 2011; Ingerski et al., 2010;Kitney et al., 2009). 
Greenley, Stephens et al. (2013) examined the adherence rates to multivitamins, iron and 
calcium supplements in 49 adolescents with ffiD in the USA and the relationship between non-
adherence and knowledge about supplements. Supplemental knowledge and adherence were 
assessed with the MAM. Results revealed that mean adherence rates ranged from 32% to 44% 
across these supplements. Approximately 25% of participants did not know the reason for 
supplements. Adolescents who lacked knowledge about all supplements displayed substantially 
poorer adherence than those with moderate or high levels of knowledge. This suggests 
know ledge of supplements is a predictor of adherence. Although the findings could have been 
affected by the subjective assessment method (self-reports on the MAM may have overestimated 
adherence), they still illuminate an important gap between a lack of knowledge and non-
adherence. Use of multiple measures of adherence and qualitative data could have allowed for 
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more careful evaluation of the levels of knowledge and adherence (Greenley, Stephens et al., 
2013). 
The only Canadian study examining medication adherence among paediatric IBD patients 
was conducted by Kitney and colleagues (2009) in Edmonton, Alberta. The purpose of this study 
was to examine adherence rates to prescribed IBD medications, non-prescribed supplements and 
self-use ofherbal medications and to determine factors affecting adherence in 119 IBD patients 
(a mean age of 13.2 ± 3.4 years). Adherence was assessed based on patient reports in a survey 
adapted from a published questionnaire. The questions used in the survey were designed to 
determine frequency and reasons for non-adherence as well as overall health awareness. 
Demographic data of the patients were obtained from chart reviews and an IBD patient database. 
Results revealed that non-adherence was significantly associated with older adolescents 
(14.6 years versus 13.0 years).Approximately 10% of patients reported using herbal medicines. 
The use of herbal medicines was found to be related to non-adherence to maintenance 
medications. Moreover, results showed that non-adherence rates were found higher in those with 
a parent or guardian education level of high school or lower. Adherent patients reported seeing 
their healthcare providers more frequently than non-adherent patients. This is the only study 
about levels of parent education and the use of herbal medications regarding medication 
adherence in paediatric IBD patients. Limitations of the findings include the subjective 
assessment of adherence and cross-sectional quantitative data. 
The other three studies identified that non-adherence was influenced by the beliefs that 
treatment was not necessary or medications were ineffective (Gray et al., 2012; Hommel, 
Denson et al., 2011; Ingerski et al., 2010). These three studies were presented in the sections of 
behavioural and psychosocial factors. They all examined barriers to adherence to 5-ASA and 6-
MP/AZA, based on adolescent and/or parent reports on the MAM, but each study had different 
foci and purposes. 
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Gray et al. (2012) focused on the negative additive impact of psychological issues on the 
relationship between barriers and adherence, and revealed that 10.1% of adolescents did not 
think the treatment necessary. Hommel, Denson et al. (2011) and Ingerski et al. (2010) both 
examined the relationship of medication adherence and perceived barriers to adherence, based on 
both adolescent and parent reports. Ingerski et al. (20 1 0) also used objective methods (pill counts 
and serum assays of6-MP/AZA) to assess medication adherence. Both studies found that the 
parents and adolescents did not believe the treatment medications were necessary. 
The above studies indicated that non-adherence was associated with knowledge and 
beliefs about IBD treatment and medications and the education levels of parents or caregivers of 
adolescents with IBD. Use of herbal medications was associated with non-adherence. This may 
reflect a lack of confidence in or distrust of the effectiveness of prescribed maintenance 
medications (Kitney et al., 2009). 
In summary, fmdings of this review implied that factors affecting adherence were 
complex and multi-factorial. Disease and medication-related factors were associated with the 
disease activity, treatment regimens and medications. Psychosocial factors were associated with 
anxiety and depressive symptoms, helplessness, dependency, low self-esteem of adolescents, 
parent-child conflicts, family dysfunction, poor coping strategies and less parental involvement. 
Common behavioural factors were identified as forgetfulness, interference with activities, not 
being home, medications not being refilled and levels of attention and conduct problems. Non-
adherence was also significantly influenced by a lack of knowledge about IBD treatment and 
medications and beliefs of the need for treatment and medications. 
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In addition to these factors, two studies revealed that demographic factors, such as age, 
gender, ethnicity and levels of family annual income, were not significantly associated with non-
adherence in adolescents with ffiD (Greenley, Stephens et al2010; lngerski et al., 2010). 
However, two other studies identified that older adolescents (15 years and older) were at greatest 
risk of poor adherence, compared with adolescents younger than 12 years (Kitney et al., 2009; 
Leleiko et al., 2013). The relationship between barriers to adherence and adherence was 
investigated in four studies (Greenley, Stephens et al., 2010; Hommel & Baldassano, 2010; 
Hommel, Denson et al., 2011; Ingerski et al., 2010). 
Of the twelve studies, eleven were conducted in the United States of America and one in 
Canada. Methods included mixed methods, both qualitative and quantitative, in one study 
(Hommel & Baldassano, 2010), qualitative with individual interviews in one study (Hommel, 
Odell et al., 2011) and quantitative in ten other studies(Gray et al., 2012; Greenley, Stephens et 
al., 2010; Greenley, Stephens et al., 2013; Hommel, Danson et al., 2011; lngerski et al., 2010; 
Kitney et al., 2009; Leleiko et al., 2013; Mackner & Crandall, 2005; Reed-Knight et al., 2011; 
Reed-Knight et al., 2013).Adherence to 5-ASA and 6-MP/AZA was also examined in five 
studies, with subjective and/or objective methods (Greenley, Stephens et al., 2013; Hommel & 
Baldassano, 2010; Hommel, Denson et al., 2011; Kitney et al., 2009; Leleiko et al., 2013). 
Findings ofliterature review about intervention strategies will be discussed in the next chapter. 
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Table 1. Factors affecting adherence to oral medications in adolescents with IBD 
Study Sample/ Tools to identify factors Commonly Indentified Factors Strengths Weaknesses Implications 
Age 
Gray Sample Medical Adherence Measure Forget, not being home, interference with Multiple factors Homogeneous Adherence was 
et al. n=79 (assessing factors and activities, refusaVdefiance,did not fill, hate examined. Sample. significantly 
(2012) Age: measuring adherence) the taste, difficulty swallowing pill, not Multi-site data Adherence lower with 
Quantitative 13-17yr Youth Self-Report feeling well, belief that medications were collected. measured with higher barriers 
(behavioural and emotional unnecessary, dislike medication side Well-validated Self report. and higher 
USA functioning over the past six effects. Anxiety/depression moderate the tools used. Cross- anxiety and 
months) relationship between barriers to adherence Adolescents and sectional data depressive 
and adherence. parents included. syll)ptoms. 
Greenley, Sample Medication Adherence Lack of time, medication side effects, Adolescents and Homogeneous Barriers to 
Stephens n=64 Questionnaires (written multiple daily doses of medications, parents included. Sample. adherence were 
et al. Age: format of the Medication feeling well, belief that medication was Cross- not consistently 
(2010) ll-18yr, Adherence Interview to ineffective. Adherence barriers were sectional data. associated with 
Quantitative assess adherence rate). significantly higher in families reporting Only six adolescent age, 
Six questions used to assess imperfect adherence compared to those barriers sex and time 
USA barriers to adherence during reporting perfect adherence. examined. since diagnosis 
the _j)ast one _y_ear. 
Greenley Sample Medical Adherence Measure Lack of knowledge about the reasons for Adherence and Small sample Lack of 
et al. n=49 (assessing knowledge about supplements (multivitamin, iron and knowledge were size. knowledge 
(2013) Age: 11- supplements as prescribed calcium regimens). Rates of non- assessed with a Adolescent- associated non-
Quantitative 18yr and measuring supplement adherence ranged from 68 to 56% cross validated tool. reports. adherence to 
adherence over the past one supplements. Poorer adherence was Focused solely supplements as 
USA week). significantly related to lower levels of on knowledge. prescribed. 
knowledge across all supplements. 
Hommel& Sample Medical Adherence Measure Forget, interference with activities, Subjective and Homogeneous Use a combined 
Baldassano n=16 (assessing factors and difficulty swallowing pill and not being objective Sample. approach to 
(2010) Age: adherence over the past home. Number of reported barriers was methods of Small sample adherence 
Quantitative l3-17yr week). Treatment Adherence positively correlated with objective adherence size. assessment. Use 
and Interview (assessing measure of non-adherence (pill count). assessment. quantitative and 
qualitative knowledge of regimens, Non-adherence frequency was 42% for 6- Quantitative and qualitative data 
USA organizational and MP/AZA and 50% for 5-ASA. qualitative data to assess factors 
behavioural factors). for assessing affecting 
factors. Inclusion adherence. 
of patients and 
parents. 
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Table I. (Continued) 
Study Sample/ Tools to identify factors Commonly Indentified Factors Strengths Weaknesses Implications 
Age 
Hommel, Sample Medical Adherence Measure. Forget, not being home, interference with Inclusion of Subjective Oppositional 
Denson n=62 Child Behaviour Check List activities, refusaUdefiance, did not fill, not adolescents and measure of behaviours, 
et al. Age: Youth Self-Report feeling well, belief that medication was parents. assessing depression and 
(20 11) l3-17yr Children's Depression unnecessary, difficulty swallowing pill, Heterogeneous adherence. anxiety are 
Quantitative Inventory. hate the taste. Perceived barriers to sample. potential 
adherence were related to non-adherence factors 
USA and increased behavioural and emotional affecting 
problems (oppositional behaviours, adherence. 
depression and anxiety, etc.) 
Hommel, Sample Treatment Adherence Forget, interference with activities, a lack A semi-structured Homogeneous Family support 
Odell n=16 Interview (assessing of planning ahead for medication-taking, open-ended Sample. and good 
et al. Age: knowledge of regimens, difficulty swallowing pills, child interview. Small sample parent-child 
(2011) 13-17yr organizational and behavioural oppositional behaviours, embarrassment Inclusion of size. relationships, 
Qualitative factors). about taking medications with peers, patients and parental 
USA regimen complexity, limited knowledge parents. monitoring and 
about IBD, treatment and medications, reminders were 
parent-child conflicts. highly valued. 
Ingerski Sample Medical Adherence Measure Forget, not being home, interference with Subjective and Homogeneous Total number 
et al. n=74 (assessing barriers to activities, refusal/defiance, did not fill, not objective (pill Sample. of barriers was 
(2010) Age: adherence and measuring feeling well, belief that medication was count, serum assay) Cross- significantly 
Quantitative 13-17yr adherence in the past one not necessary. Fewer total reported methods of sectional data. correlated to 
week). barriers was related to better adherence. assessing adherence. 
USA Demographic was not related to the total adherence. 
number of reported barriers. Multi-site data 
collections. 
Adolescents and 
_l)arents included. 
Kitney Sample A survey (published Forget, feeling better, too many Descent sample One Pay attention to 
et al. n=ll9 questionnaire with 24 domains medications, lower level of parent size. subjective use of herbal 
(2009) Mean to determine frequency and education, multiple daily doses and Heterogeneous measure of medications in 
age: reasons for non-adherence to infrequent clinic visits. Non-adherence sample. adherence. IBD patients, 
Quantitative 13.2±3.4 IBD prescribed medications, was significantly associated with older age Cross- educate them 
vitamins and complementary (14.6 yr versus 13.0 yr), longer disease sectional data the possible 
Canada medicines in the past three duration, and use of herbal medications, drug 
months) but not demographics (gender, place of interactions. 
residence, ethnicity or first language). 
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Table 1. (Continued) 
Study Sample/ Tools to identifY factors Commonly lndentified Factors Strengths Weaknesses Implications 
Age 
Leleiko Sample Child Behaviour checklist. Adolescents aged 15 yr or older had Well-established Use of Screen for 
eta!. n=79 Children's Depression Inventory. significant lower adherence rates to 5- measures of behavioural medication emotional and 
(2013) Age: Multidimensional Anxiety Scale for ASA and6-MP/AZA compared with and emotional issues. electronic behavioural 
Quantitative 8- Children. younger adolescents. Behavioural and Descent sample size. monitoring problems, 
17.5yr emotional issues were significantly Study over a 6-month devices as a especially among 
related to non-adherence. period. single measure older 
USA of adherence adolescents. 
Mackner Sample Parents completed medication Family dysfunction, child poor coping Well-validated Use of Monitor family 
& n=50 adherence interview, the Child strategies and behavioural/emotional measures. Patients and interview as a dysfunction, 
Crandall Age: Behaviour Checklist, Family problems were significantly associated adolescents were sole measure of adolescent 
(2005) 11-17yr Assessment Device and demographics with non- adherence. Demographic and interviewed separately adherence. behavioural and 
Quantitative questionnaires. Separately, adolescents treatment regimen factors were not by personnel who did emotional 
completed medication adherence associated with non-adherence. The not provide direct problems, poor 
interview, the Piers Harris Self-Concept rates of non-adherence were 52% medical care. coping strategies 
Scale, Children's Depression Inventory adolescent reported and 62% parent Heterogeneous sample. and consider 
USA and Coping Strategies Inventory reported. Descent sample size. psychotherapy. 
questionnaires. 
Reed- Sample The Motivation subscale of the Longer time since diagnosis, a lack of Inclusion of patients Subjective Address 
Knight n=90 Treatment Self-Regulation motivation to adherence, parent-child and parents. Inclusion measure of motivation and 
eta!. Age: Questionnaire. IBD Family conflict and less maternal involvement. of prescription and adherence. parent-child 
(2011) 11-18yr Responsibility Questionnaire (assessing over-the-counter Homogeneous conflict, 
Quantitative adolescent and maternal involvement). medications. sample. encourage Issues Checklist (assessing common Descent sample size. Cross-sectional maternal 
sources of conflict) . Medical Adherence data. involvement 
USA Measure (assessing adherence and 
knowledge of medications) 
Reed- Sample Medical Adherence Measure (assess Attention problems and conduct Inclusion of parent and Subjective Barriers to 
Knight n=85 adherence over the past one symptoms (e.g., rule breaking, lying) adolescent. Validated measure of adherence 
eta!. Age: week).Parent/ Adolescent Medication interfered with adherence. Barriers to questionnaire measuring adherence. contribute to the 
(2013) 11-18yr Barriers Scales (assessing parent- and adherence included forgetfulness, poor attention and conduct Homogeneous relationship 
Quantitative adolescent-reported barriers) organization/planning, being busy, problems. sample. between attention Behaviour Assessment System for relying on a parental reminder. Barriers Cross-sectional and behavioural 
Children (assessing attention and mediated the effects of attention and data. problems and 
USA conduct problems by parents. conduct problems. adherence. 
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Chapter Four: Intervention Strategies to Improve Medication Adherence 
Given the high rates of non-adherence in adolescents with ffiD and its significant impacts 
on individual health outcomes and healthcare costs, development and implementation of 
intervention strategies to target specific factors affecting adherence is imperative. For this 
purpose, a total of eight studies were retrieved and reviewed to answer the second research 
question: "What are the intervention strategies that FNPs can use to promote oral medication 
adherence in adolescents with ffiD?'' 
Literature is limited on intervention strategies for non-adherence in adolescents with ffiD. 
Of the eight studies, four were focused on adolescents aged 11 to 18 years with smaller sample 
sizes. Four other studies were focused on adult patients and adolescents aged 17years and older. 
These four studies involved older adolescent patients and had larger sample sizes. Therefore, 
they were included to provide a broader research-based evidence of intervention strategies. 
Among the eight studies, one study was conducted in Canada (Waters, Jensen, & 
Fedorak, 2005), one in Denmark and Ireland (Elkjaer et al., 2010), one in the United Kingdom 
(Moshkovska, Stone, Smith, Bankart, Baker, & Mayberry, 2011) and five in the USA (Cook, 
Emiliozzi, EI-Hajj, & McCabe, 2010; Greenley et al., 2011; Hommel, Herzer et al., 2011; 
Hommel et al., 2012; Hommel, Hente, Herzer, Ingerski, & Denson, 2013). 
The intervention strategies provided in these studies included behavioural, psychosocial, 
educational and multi-component interventions. These interventions were justified with the 
factors identified in the previous literature review (See Chapter three), because they targeted 
disease and medication-related factors (such as complex dosing regimen, adverse effects of 
medications), psychosocial issues (such as depression, anxiety, psychosocial distress, low 
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motivation), behavioural problems (such as forgetfulness, oppositional behaviours) and a lack of 
knowledge about the disease, maintenance treatment and medications. 
Multi-component intervention strategies were evaluated in four studies (Hommel et al., 
2012; Hommel, Rente et al., 2013; Hommel, Herzer et al., 2011; Moshkovska et al., 2011). No 
study was found to evaluate behavioural interventions as a single intervention strategy. Instead, 
behavioural interventions were provided as part of multi-component interventions. Psychosocial 
interventions were provided as a single strategy in two studies (Cook et al., 201 0; Greenley et al., 
2011). Educational interventions were provided as a single strategy in two studies (Elkjaer et al., 
2010; Waters et al., 2005). 
Adherence interventions, methods of adherence assessment, intervention outcomes of 
each study, along with its strengths and weaknesses were examined and presented in Table 2. 
Multi-component interventions will be presented first, followed by behavioural interventions, 
psychosocial interventions and educational interventions. 
Multi-component Interventions 
Multi-component intervention strategies combined educational, behavioural, or 
psychosocial interventions (Greenley, Kunz, Walter, & Hommel, 2013). These interventions 
focused on behavioural and emotional problems, a lack of knowledge and psychosocial issues of 
adolescents and families, which were identified associated with non-adherence and reviewed in 
Chapter three. Given that factors affecting medication adherence are complex and multi-factorial 
in adolescents with ffiD, using multi-component interventions was reasonable. 
Four studies provided the evidence to support the efficacy of multi-component 
interventions on adherence in adolescents with ffiD (Hommel et al., 2012; Hommel, Rente et al., 
2013; Hommel, Herzer et al., 2011; Moshkovska et al., 2011). Approaches to multi-component 
47 
interventions were different in these four studies, depending on the purpose of each study. An 
individually tailored intervention was delivered in a clinical setting in Hommel, Herzer et al. 
(2011). An individually tailored intervention was delivered through online Skype in Hommel, 
Rente et al. (2013). A family-based group intervention was provided in a clinical setting in 
Hommel et al. (2012). In these three studies, multi-component interventions were delivered by 
doctoral level clinical psychologists or postdoctoral psychology fellows. A one-on-one education 
and motivation program was provided by the researchers (Moshk.ovska et al., 2011). 
Hommel, Herzer et al. (2011) conducted a pilot randomized trial in a clinical setting to 
evaluate the feasibility, acceptability and efficacy of an individually tailored, multi-component 
approach that targeted educational, behavioural and psychosocial factors related to adherence. 
These multi-component interventions focused on educational and behavioural interventions, 
problem solving skills and adolescent/family psychosocial support. Fourteen adolescents with 
IBD aged 11 to 18 years were randomly assigned to an immediate care group or a wait list 
control group. Patients in the immediate care group attended four weekly intervention sessions, 
each session lasting 60-75 minutes. The interventions were provided by doctoral-level clinical 
psychologists or postdoctoral fellows. Medication adherence was measured with pill count at 
each visit. 
Results revealed that improvements in adherence were substantially better for 5-ASA 
(mesalamine) than for 6-MP/AZA, with an increase of 4% of adherence to 6-MP/AZA and an 
increase of 25% of adherence to 5-ASA. The 100% retention rate of patients indicated the four-
session interventions were a feasible approach for improving adherence. Additionally, the 
interventions were rated favourably in terms of acceptability by both patients and parents, 
suggesting that a multi-component individually tailored approach is a viable intervention 
strategy. 
Hommel et al. (2012) conducted a randomized-controlled trial of a family-based group 
intervention in 40 adolescents with illD aged 11-18 years. They provided similar multi-
component interventions used in Hommel, Herzer et al. (2011), including educational and 
behavioural interventions, problem solving skills and adolescent/family psychosocial support. 
These interventions targeted educational, behavioural and psychosocial factors related to 
adherence, and were delivered in a clinical setting. The purpose of this trial was to evaluate the 
feasibility, acceptability and efficacy of a family-based group approach to multi-component 
interventions to improve medication adherence. 
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Forty adolescents with their parents were randomly assigned to a family-based 
intervention group (n = 20) and a usual care group (n = 20). Participants in the intervention 
group attended four weekly family-based group intervention sessions led by doctoral level 
clinical psychologists or postdoctoral psychology fellows. Patients in the control group received 
standard care over a 6-week period. There were no significant differences between the two 
groups at baseline across demographic, disease activity and adherence parameters. Medication 
adherence to 5-ASA (mesalamine) and 6-MP/AZA was assessed with adolescent and parent 
reports, pill count and electronic medication monitoring. 
Results revealed no significant differences between the intervention and usual care 
groups from baseline to post intervention assessments across pill counts, electronic monitor and 
parent-reported adherence. From adolescent-reports, there was no significant difference for 
adherence to 6-MP/AZA between the two groups, but there was a significant increase (25%) in 
5-ASA adherence in the intervention group, whereas there was only a 1% increase in 5-ASA 
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adherence in the usual care group. Excellent feasibility was demonstrated by the 99% attendance 
in the intervention group. The intervention was also highly acceptable to both patients and 
parents, as evidenced by 70-100% reporting a high degree of acceptability. 
This trial utilized a multi-method, multi-informant assessment approach to compensate 
for the limitations of each measure. However, the fmdings are limited by the small sample size 
and homogenous sample. There were some unseen challenges for using electronic monitor 
devices in participants, which could affect the adherence results. High baseline levels of 
adherence across self-report assessment might have prevented significant differences in 
adherence between the two groups (Hommel et al., 2012). 
Hommel, Hente et al. (2013) conducted a single-arm pilot clinical trial in adolescents 
with IBD. They provided the same intervention strategies used in Hommel, Herzer et al. (20 11 ), 
i.e. an individually tailored, multi-component intervention approach that targeted educational, 
behavioural and psychosocial factors related to adherence. The multi-component interventions 
included educational and behavioural interventions, problem solving skills and adolescent/family 
psychosocial support. But the interventions were delivered through tele-health (skype) with 
patients and families, not through clinic visits. The purpose of this trial was to evaluate the 
feasibility, acceptability and preliminary efficacy of this tele-health-based approach to improve 
medication adherence and reduce costs. 
Nine adolescents with IBD aged 11-18 years and their parents completed four weekly 
intervention sessions, each session lasting 60-90 minutes though Skype and webcam. Patients 
and parents were seen independently, without other families present. Interventions were provided 
by doctoral-level clinical psychologists or postdoctoral clinical psychology fellows. Each patient 
was treated by the same clinician for the duration of their treatment. Medication adherence to 5-
ASA and 6-MP/AZA was measured with pill count over the telephone at baseline and post-
intervention time points. Baseline and post-treatment measures were completed by participants 
and were mailed to study staff. 
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Results revealed that there was a marked increase in 5-ASA adherence from 62% at 
baseline to 91% post intervention. But, adherence to 6-MP/AZA decreased modestly from 61% 
to 53% post intervention. The feasibility was indicated by 100% attendance for all participants in 
the trial. Acceptability ratings by patients and parents were highly favourable and ratings of 
convenience were high, with 78% of patients and parents providing ratings in the ideal range. 
Utilizing this tele-health approach resulted in a per-patient cost savings of over $100 and more 
than 4 hours of travel time over the course of treatment. Findings suggest that a tele-health 
approach to individually tailored, multi-component interventions is feasible, acceptable and 
shows preliminary efficacy of improving medication adherence. 
Both Hommel, Herzer et al. (2011) and Hommel, Rente et al. (2013) had similar 
limitations, such as small sample size, homogeneous sample and a single measure for adherence 
assessment (pill count). The two studies revealed a better improvement in adherence to 5-ASA 
than to 6-MP/AZA. The discrepant effects of the two medications may suggest there is an 
unknown barrier to 6-MP/AZA adherence. This may also be related to the difference in regimen 
complexity of these two medications (6-MP/AZA usually requires 2-3 times daily and 5-ASA 
requires once daily). However, the findings of these two studies imply that individually tailored, 
multi-component interventions, delivered either via tele-health or in a clinical setting, are 
feasible, acceptable and effective in promoting medication adherence. 
Similar multi-component interventions were provided and delivered with different 
approaches in the above three studies (Hommel, Herzer et al., 2011; Hommel et al., 2012). 
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Hommel, Rente et al., 2013). These studies revealed the feasibility, acceptability and efficacy of 
multi-component interventions to improve medication adherence in adolescents with ffiD, either 
an individually tailored approach in a clinical setting, via Skype, or a family-based group 
approach in a clinical setting. 
Moshkovska et al. (2011) conducted a study among 71 patients aged 18 to 80 years on 5-
ASA for maintenance treatment ofUC. The purpose of this study was to evaluate the impact of 
multi-faceted interventions on adherence to 5-ASA in patients with UC, changes in health beliefs 
and satisfaction with information. The interventions included educational, motivational and 
behavioural components tailored to patient preferences. Patients in the intervention group 
attended a one-on-one education and motivation session conducted by the researchers. They 
were also offered up to three practical adherence enhancing interventions, including simplifying 
of dosing regimen (if clinically appropriate), medication reminder charts, visual medication 
reminders, daily/weekly electronic pillbox organizers, or mobile telephone alarm set-up. Patients 
in the control group received standard prescribed care from their clinical team. 
Medication adherence was objectively assessed based on the levels of urinary 5-ASA and 
N-acetyl-5-ASA concentration at baseline, mid-study (24 weeks) and at the end of study (48 
weeks). Disease flare-up data were collected from medical records during the study period. A 
flare-up was defined as an unscheduled hospital appointment or admission related to UC. 
Changes in health beliefs and satisfaction with information were measured using validated 
questionnaires. Results revealed that at follow-up adherence in the intervention group was 44% 
greater than in the control group. Changes in questionnaire scores suggested a positive effect of 
these combined interventions on patient knowledge, satisfaction with information and greater 
adherence in the intervention group. 
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Although it is difficult to accurately assess the contribution made by the various 
components of multi-faceted interventions, this study suggested combining interventions tailored 
to individual preference of practical reminders was an effective way of improving adherence to 
5-ASA. There are several limitations to this study, such as a relatively small sample size and a 
single measure used for adherence assessment. This study was focused on patients aged 18 years 
and older. It is difficult to know whether these interventions would apply directly to adolescents 
who are 17 years and younger. Further studies exploring the impact of this approach to 
adolescents with IDD are therefore required. 
Behavioural Interventions 
Behavioural interventions aim to reinforce medication adherence by providing practical 
strategies, include using different type of reminder systems, daily/weekly pillbox organizers, 
development of behavioural contracting or reward systems. Dosage simplification was 
considered one component of behavioural interventions (Greenley, Kunz et al., 2013). 
Behavioural interventions were provided in conjunction with other interventions in three studies 
using multi-component interventions (Hommel, Herzer et al., 2011; Hommel et al., 2012; 
Moshkovska et al., 2011 ). These studied were reviewed in the above section on multi-component 
interventions. 
In Moshkovska et al. (20 11 ), three practical strategies: were used, including simplifying 
of dosing regimen (if clinically appropriate), medication reminder aids (charts, visual and audio 
reminders), or use of daily/weekly electronic pillbox organizers. These practical interventions 
targeted forgetfulness and complex medication regimens. As part of multi-component 
interventions, these practical interventions were tailored to an individual preference that may 
have played a role in the significant improvement to adherence to 5-ASAin this study. 
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In addition to these practical interventions, development of behavioural contracting or 
reward systems was also provided in multi-component interventions in Hommel, Herzer et al. 
(2011) and Hommel et al. (2012). Behavioural contracting or reward systems targeted on 
adolescents who had attention conduct problems, low motivation, or oppositional behaviours. 
These studied demonstrated that behavioural contracting and reward systems, when used 
appropriately in combination with other interventions, contributed to improvement of adherence. 
These were particularly helpful for adolescents with oppositional behaviours and/or low 
motivation to adhere to medications. 
Behavioural factors were identified correlated to other factors contributing to non-
adherence, such as psychosocial factors or a lack of knowledge about the disease, treatment 
regimens and medications. Psychological issues affected the relationship between behavioural 
factors and medication adherence (Gray et al., 2012; Mackner & Crandall, 2005). Therefore, 
behavioural interventions were provided in combination with psychosocial or educational 
interventions to improve medication adherence in adolescents with IBD. 
Psychosocial Interventions 
Psychosocial interventions included cognitive-behavioural interventions and problem-
solving skills training to support adolescents and families. Cognitive-behavioural interventions 
enhanced adherence by altering thinking patterns that contributed to non-adherence while also 
establishing behavioural patterns that supported adherence using behavioural intervention 
strategies (Greenley, Kunz et al., 2013). Psychosocial interventions were provided as a single 
intervention strategy in two studies (Cook et al., 2010; Greenley et al., 2011). They were also 
provided in multi-component interventions in three other studies (Hommel, Herzer et al., 2011; 
Hommel et al., 2012; Hommel, Hente et al., 2013). 
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Cook et al.(2010) conducted a preliminary test of telephone nurse counselling to address 
cognitive and emotional barriers to medication adherence in 278 patients with UC aged 18 years 
and older. The purpose of this study was to evaluate the effects of motivational interviewing and 
cognitive-behavioural techniques (CBT) on adherence to 5-ASA (mesalamine). Interventions 
were delivered by a registered nurse (RN) who received training on CBT and motivational 
interviewing counselling techniques. During phone calls, the RN assessed adherence and offered 
interventions, using motivational interviewing questions to reduce ambivalence about treatment, 
and using CBT to address negative beliefs about treatment and help patients cope with adverse 
drug effects. 
All participants received telephone follow-ups. On average, two more calls from the RN 
were made at different times on different days of the week. Written materials that addressed 
cognitive barriers (e.g., information about UC and 5-ASA) or emotional barriers to adherence 
were mailed to participants. The referring healthcare provider received a progress note after each 
call, noting the participant's adherence level and any concerns. Up to 6 months, adherence to 
mesalamine was measured by a structured interview and was compared to mesalamine adherence 
of an expected population rate using a binomial test. After 6 months patients at low-risk for non-
adherence were called once and patients at high risk for non-adherence received additional calls 
from the same RN. 
Disease and medication-related factors were tackled through the interventions. The RN 
addressed adverse effects of medications and symptoms associated with the disease activity, 
helped patients cope with these issues and effectively communicate with healthcare providers 
about their concerns. Results revealed that patients' 6-month adherence was significantly higher 
than the expected rate in a similar population. This study suggested telephone nurse counselling 
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to address cognitive and emotional barriers was feasible to improve mesalamine adherence in 
patients with UC. Because this was a pilot study and used self-report data for adherence 
assessment, results require further confirmation in a randomized control trial with more objective 
adherence data. 
Greenley et al. (20 II) conducted a randomised trial to evaluate the acceptability and 
feasibility of a phone-delivered problem-solving skills training (PSST) intervention to reduce 
adherence barriers and improve adherence to maintenance medications in adolescents with ffiD. 
PSST consisted of teaching families a structured approach to defining problems and generating 
and evaluating solutions. Thirty-three participants (parent-child dyads or triads) were randomised 
to either to immediate treatment and a wait list comparison (control) group. In the immediate 
group, 15 adolescents aged 11-18 years and their parents completed a baseline assessment of 
adherence barriers, as well as assessments at the midway point and post intervention. Those in 
the immediate treatment group received four phone intervention sessions. 
Medication adherence was assessed with electronic monitoring. Knowledge about ffiD, 
management regimens and family problem solving skills were assessed with patient and family 
reports. Compared with the control group, medication adherence was significantly improved in 
the immediate group. More than 70% of parents and adolescents indicated increased knowledge 
about ffiD and management regimens, improved family problem solving skills, and the 
intervention helped them to identify barriers to adherence. Moreover, 78% of parents and 80% of 
adolescents reported plans to use solutions generated in PSST in medication regimen 
management. Findings were limited by the homogeneous and small size sample. However, data 
were analyzed both subjectively (patient/family reports) and objectively (electronic monitoring). 
This study supports a phone-delivered PSST as an acceptable and feasible method of 
intervention to reduce adherence barriers and improve adherence in adolescents with IBD. 
Educational Interventions 
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A lack of knowledge about the disease, treatment regimens or medications was identified 
to be associated with non-adherence in adolescents with IBD. Educational interventions aim to 
improve patient knowledge of the disease, treatment regimens and mechanisms of medications, 
enhance patient motivation and increase their awareness of consequences of non-adherence 
(Greenley, Kunz et al., 2013). Educational interventions were provided either as a single strategy 
or as part of multi-component intervention strategies. 
The effects of educational interventions as a single intervention strategy were evaluated 
in two studies, but with different formats of education (Elkjaer et al., 201 0; Waters et al., 2005). 
Waters et al. (2005) provided a formal IBD education program designed and delivered by a 
gastroenterology nurse practitioner in a clinical setting. Elkjaer et al. (2010) provided web-based 
specific education and constant care using e-health resources. 
A formal educational intervention was developed and evaluated by Waters et al. (2005). 
The purpose of this study was to assess the effects of increased knowledge on medication 
adherence in patients with IBD aged 17 and older. Sixty-nine patients were randomly assigned to 
a formal IBD education group (n = 38) or standard of care group (n = 31 ). Patients in the formal 
IBD education group, in addition to standard of care, attended a 12-hour, structured education 
program provided in 3-hour blocks over four consecutive weeks. Patients in the standard of care 
group were provided with educational pamphlets and regular physician education. 
Medication adherence was assessed with self-reports. Knowledge was assessed in diet, 
gut anatomy and physiology, general IBD knowledge, complications and medications. 
Healthcare use was assessed with records of physician visits and hospital admissions related to 
IBD and the associated complications. Patient satisfaction with medical care and the education 
program was assessed with questionnaires. 
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Results revealed that the formal IBD education group had a lower rate of non-adherence 
and healthcare use compared to the standard of care group, but the differences were not 
significant. The education group demonstrated significantly higher knowledge scores compared 
to the standard of care group. Patients' satisfaction ratings were high for both groups, but the 
education group had a significantly greater degree of patient satisfaction. Findings of this study 
may be limited by the subject reports as a sole measure of adherence and time constrains on part 
of patient and provider. 
Elkjaer and colleagues (2010) evaluated the effects of web-based specific IBD education 
on medication adherence, disease outcomes and healthcare costs. This study was undertaken in 
Denmark and Ireland. A total of333 patients aged 18 to 69 years on 5-ASA maintenance 
treatment for UC participated. Patients were randomized to either a web-based group (n = 169) or 
a control group (n = 164). Patients in the web-group were provided access to a 3-hour, web-
guided specific education session about IBD aetiology, pathology, disease course, adherence and 
complications ofiBD. Patients in the control group continued the conventional treatment and 
follow-ups in the IBD outpatient clinic. Patients in the two groups could contact the web-doctor 
by e-mail, text messages or phone calls. 
Medication adherence was assessed with refilling of medications from the e-prescription 
pharmacy database. At 12 months, adherence was improved significantly in web-patients. More 
than 88% of the web patients found this new approach feasible and wanted to continue using it. 
At the end of the trial, a significant improvement in IBD knowledge and medication adherence 
was observed in the web group compared to the control group. No significant difference in 
relapse frequency was observed between the two groups during the study period, but median 
days of relapses in the web group were of a shorter duration than in the control group. 
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The number of visits to the outpatient clinic was significantly lower in the web than in the 
control group. Moreover, during 12 months web-patients contacted the web doctor more often 
than control-patients. The numbers of contacts were converted into a saving of 189 euro per 
patient per year for the out clinic (about 265 Canadian dollars per patient per year). The strengths 
of this study include large sample size, multi-component, multisite data collection and a longer 
period of study. Results of medication adherence may be limited by using an objective 
assessment as a single measure. Findings indicate the web-guided approach is feasible and cost 
effective in improving adherence to maintenance medications in UC. This web-based, specific 
ffiD educational intervention was targeted to older adolescent and adult patients, but might not 
be appropriate for younger adolescents. 
In summary, intervention strategies for improving medication adherence aimed to target 
multi-factorial barriers to adherence, such as complex treatment regimens, medication side 
effects or adverse drug events, emotional and behavioural problems, problem solving skills, 
knowledge about the disease, treatment and medications. Educational, psychosocial, behavioural 
or multi-component interventions were delivered individually or in a group setting, via telephone 
calls, websites, or during clinical visits. Compared with group-based interventions that focus on 
issues shared by multiple families, an individually tailored intervention provides more time for 
individualized problem solving of families' unique barriers. A multi-component individually 
tailored approach appears a promising intervention option. 
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Findings of the review are limited by the paucity ofliterature. However, they provide 
implications for the role ofFNPs in promoting medication adherence. Discussion of implications 
and recommendations for FNP practice, education and research will be provided in next chapter. 
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Table 2. Intervention strategies for improving adherence to oral medications in adolescents with IBD 
Study Sample (n) Adherence interventions Methods of Intervention outcomes Strengths Weaknesses 
Age (yr)/ adherence 
Diagnosis assessment 
Cook n=278 Telephone counselling conducted by a Patient Overall, participants' 6-month Large sample size. Pre-post design, 
et al. Age: RN who used cognitive-behavioural report with adherence was significantly Multi-component with no control 
(20IO) I8 yr and techniques and motivational structured higher than the expected strategies. Telephone group. Increase 
older, interviewing, reinforced with written interview. population rate. Self-efficacy counselling workload for 
uc follow-up materials that were sent to 5-ASA predicted adherence, not inexpensive and RNs.RNs 
USA patients (M= 2.I calls). demographic and clinical feasible, reduces received special 
variables did not. _Qatient travel. training. 
Elkjaer n= 333 Web-based intervention strategy. E-pharmacy Medication adherence, IBD Large sample size. Significant cost 
et al. Age: Patients in a web-group (web-guided database for knowledge was significantly Multi-component, associated with 
(20IO) I8-69 yr, approach via www. constant-care.dk) adherence improved in the web-group multisite RCT. use of automated 
uc received constant care with specific to 5-ASA patients. Median relapse Wide age range and tracking system. 
Denmark education and self-treatment for I2 maintenance duration was I8 days in the web large sample size. 
And months. Interaction with a physician therapy. group versus 77 days in the Education and 
Ireland through e-mail, text messages or control group. The number of feedback on IBD 
phone was also provided. visits to the outpatient clinic symptoms using an 
Patients in a control group continued was lower in the web than in automated system 
the usual care. the control group, resulting in a reduced provider 
saving of I89 euro/patient/year. burden. 
Greenley n= 3I Phone-delivered cognitive behavioural Electronic Increased knowledge of IBD Randomized trial. Small sample 
et al. Age: problem-solving skill training (PSST) monitoring, and treatment regimen, Multiple measures of size, single 
(20 II) II-I8 yr, intervention (2 phone sessions). PSST patient and improved families' problem adherence. Telephone method of 
IBD consists of teaching patients and parent solving skills, helped to identify delivered intervention adherence, 
parents a structured approach to reports. adherence barriers and plan to reduces patient travel. interventionists 
USA defining problems and generating and use solutions generated in had psychology 
evaluating solutions. PSST. background. 
Hommel n= I4 Four weekly sessions of family-based Pill count. Adherence to 6-MP in Randomized trial. Small sample 
et al. Age: individually tailored multi-component Patient and intervention group significantly Subjective and size, lack of 
(20 II) II-I8 yr interventions, targeting educational, parent increased compared with objective methods of socioeconomic 
IBD organizational, behavioural and family report, controls, but no significant adherence assessment. and ethnic 
factors (problem solving skills and 5-ASA difference in adherence to 5- diversity, 
USA adaptive family functioning), each 6-MP/AZA ASA. Intervention resulted in a interventionists 
session 60-75 minutes. 4% gain of adherence in 6- had graduate-
MPIAZA and a 25% gain in 5- level training in 
ASA from baseline to post- psychology. 
intervention. 
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Table 2 (continued) 
Study Sample (n) Adherence interventions Methods of Intervention outcomes Strengths Weaknesses 
Age (yr)/ Adherence 
Diagnosis assessment 
Hommel n=40 Four weekly sessions of group- Patient and Adherence rates increased from Randomized trial, Small sample size, 
et al. Age: based multi-component caregiver 66% to 89% for 6-MP/AZA with family-based lack of 
(20 12) ll-18yr interventions, targeting report, and 51% to 93% for 5-ASA intervention and socioeconomic and 
IBD educational, organizational, pill count, across assessment methods. usual care groups. ethnic diversity, 
behavioural and family factors electronic Patient reported a significant Multiple methods interventionists had 
(problem solving skills, adaptive monitoring. improvement in adherence to 5- of adherence graduate-level 
The USA family functioning) over 6 weeks, 5-ASA ASA, but not significant for 6- assessment. training in 
each session 60-90 minutes. 6-MP/AZA MP/AZA. psychology. 
Hommel n=9 Individually tailored intervention Patient and Adherence increased from 62% Subjective and Small sample size, 
et al. Age: through tele-health delivery caregiver at baseline to 91% for 5-ASA, objective methods lack of 
(2013) 11-18 yr (online Skype and webcam), report, but decreased slightly from of adherence socioeconomic and 
IBD targeting educational, pill count, 61% to 53% for 6-MP/ AZA. assessment. ethnic diversity, 
organizational, behavioural and 5-ASA interventionists had 
family psychosocial factors. Four 6-MP/AZA graduate-level in 
USA weekly sessions, each 60-90 psychology. 
minutes. 
Moshkovska n= 71 Tailored patient preference Urinary 5- Adherence in the intervention Randomized trial, Single measure of 
et al. Age: intervention over 48 weeks, ASA levels. group was 44% greater than in intervention group adherence 
(20 11) 18-80 yr including educational and 5-ASA the control group, but no (one-on-one )and assessment. 
uc motivational components, options significant difference in the two control group Significant time 
The United of simplified dosing regimen and groups. Intervention group (standard care), commitment on 
Kingdom practical reminders. status had a significant positive conducted by the patients and 
(UK) impact on maintaining researchers. providers. 
adherence levels. 
Waters n=69 Formal education intervention in Survey, The intervention group had Randomized trial, Subjective 
et al. Age: 3- hour blocks over 4 consecutive validated significantly higher knowledge intervention group adherence 
(2005) 17yr and weeks, including general questionnaires, scores, significantly greater (education with assessment. 
older information about IBD, treatment patient self degree patient satisfaction and a standard care) and Significant time 
Canada IBD and group discussion of worries report. lower rate of medication control group commitment on part 
and concerns. Individual dietary adherence, but no significant (standard care). of patient and 
counselling. Assessment of difference. Increased healthcare Education providers 
knowledge ofiBD and quality of use significantly correlated with program designed 
life at baseline, immediately and 8 poorer medication adherence. and provided by 
weeks post-education. nurse practitioner. 
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Chapter Five: Implications and Recommendations 
This paper was an initial review of factors affecting medication adherence in adolescents 
with IBD and intervention strategies to improve medication adherence. To explore the role of 
FNPs in promoting medication adherence, implications and recommendations for FNP practice, 
education and research will be discussed. 
Implications and Recommendations for FNP Practice 
Findings from the reviews have implications for FNPs to engage in collaborative practice 
within a multidisciplinary team, and apply the BPS model to support the psychosocial wellbeing 
of adolescents and families. A stepwise approach to medication adherence is recommended, 
including measuring adherence, identifying factors affecting adherence and implementing 
individualized interventions targeting specific factors. 
Engaging in Collaborative Practice 
A team that may include paediatricians, gastroenterologists and nutritionists primarily 
cares for children and adolescents with IBD. Other healthcare professionals may also be 
involved, such as psychiatrists, gastrointestinal nurse specialists, social workers, or adjunctive 
paediatric subspecialists, such as rheumatologists, ophthalmologists, dermatologists and 
endocrinologists (Bousvaros & Leichtner, 2014). Although maintenance medications for IBD are 
initiated by specialists or physicians, according to the Scope of Practice for Nurse Practitioners 
(CRNBC, 2012), FNPs are able to continue prescribing 5-ASA and 6-MP/AZA, and provide 
continuity of support and care to adolescents and families based on the longitudinal relationship 
they have with patients and families in a primary care setting. FNPs have a role in promoting 
medication adherence in collaborative practice. They need to collaborate and consult with 
physicians, specialists, psychiatrists and other healthcare professionals, and work with nurses, 
pharmacists together in a multidisciplinary team to manage medication adherence. 
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Given the role in primary care, FNPs can be important resources to facilitate and 
encourage optimal medication adherence. Through follow-up visits for adolescents who are 
stable and/or require medication monitoring, FNPs are able to assess adolescents who are non-
adherent or at risk for non-adherence, identify factors affecting medication adherence, monitor 
medication side effects, adverse effects or drug toxicity, provide interventions to maximize 
medication adherence and assist patients to optimize health outcomes. Through engagement in 
collaborative practice in a multidisciplinary team, FNPs can serve as a liaison between 
patients/families and healthcare providers, consulting physicians, specialists and other healthcare 
professionals and referring patients to other professionals for early interventions as needed. 
Applying the BPS Model 
Given the significant of psychosocial issues associated with IBD and non-adherence in 
adolescents with IBD, applying the BPS model will facilitate FNPs to manage medication 
adherence. Psychological issues influence adolescents and parents' coping strategies and 
problem-solving skills and affect quality oflife and medication adherence (Mackner & Crandall, 
2005). The interactions between disease and medication-related factors and psychosocial issues 
should be integrated into the assessment of medication adherence. FNPs need to understand the 
interplay between psychosocial issues and maladaptive behaviours and coping strategies, and 
explore how adolescents deal with stressful situations. FNPs need to have knowledge about the 
appropriate tools to assess the psychological functioning of adolescents and families. 
Family is undisputed as the primary social context for children. Parent-child conflicts, 
family dysfunction, poor coping strategies and less parental involvement affect medication 
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adherence among adolescents with IBD (Mackner & Crandall, 2005). Parents may continue to 
assume full responsibility for their adolescent's medical management, which may conflict with 
the adolescent's desire to develop independence, resulting in parent-child conflicts. On the other 
hand, parents may tum full responsibility over to the adolescent. The adolescent may stop taking 
medications unknown to the parents, if he fails to see the consequences of not taking 
maintenance medications. 
Therefore, FNPs need to assist parents and adolescents to share responsibility for taking 
medications, manage parent-child conflicts, anticipate and reduce barriers to adherence. 
Particular attention should be paid to the families that lack appropriate child discipline and 
family cohesion, and the parents who have psychosocial distress and poor coping strategies. 
Providing families with information or referral for assistance with regard to forming partnerships 
between parents and adolescents, sustaining parental involvement and minimizing conflicts 
between adolescents and their parents are valuable in encouraging adherence to treatment 
regimens. 
A positive social network serves preventive as well as ameliorative functions in those 
experiencing various kinds of stress. When assessing psychosocial functioning in adolescents, 
FNPs should pay attention to any social withdrawal, interpersonal difficulty with peers, difficulty 
participating in school and social activities. FNPs can advocate for resources and social supports 
for children with IBD and encourage patients and parents to participate in support groups, such 
as the Crohn's and Colitis Canada camp held at community levels or province and national 
levels. Attending an IBD camp or activities may improve social interactions and quality of life of 
IBD patients (CCC. 2014). In conclusion, attention to psychosocial issues with the BPS 
perspectives will facilitate FNPs to improve medication adherence in adolescents with IBD. 
A Stepwise Approach to Medication Adherence 
In conjunction with the BPS model, a stepwise approach to management of medication 
adherence is recommended for FNP practice. First, FNPs need to measure adherence with a 
combined subjective and objective method. Second, once the levels of non-adherence are 
identified, FNPs need to factors affecting adherence with validated assessment tools. Third, 
FNPs need to implement relevant interventions targeting specific factors. 
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Measuring medication adherence. The methods used to assess adherence have an 
impact on the estimates of adherence. It is important to understand the strengths and drawbacks 
ofboth subjective and objective methods of measuring medication adherence. The majority of 
the studies of adherence in IBD rely on subjective self-reports using standardized interviews and 
questionnaires. FNPs should keep in mind that self-ratings on subjective measures tend to 
overestimate medication adherence. At least two measures of adherence should be used to 
measure medication adherence in adolescents with IBD, including one objective measure. When 
using bioassays to assess medication adherence, FNPs should be aware that adolescents may 
intentionally take medications prior to lab work. Random urine screening for a salicylate level 
may be a better choice if clinically applicable, as it has a better indication of medication 
adherence to 5-ASA (Gifford et al., 2012). 
Using standardized interviews and/or questionnaires to quantify adherence may be 
somewhat time-consuming during a clinic visit because of its length, such as the MAM. FNPs 
should use this scale, if a visit can be dedicated to assessing adherence. The Morisky Medication 
Adherence Scale (MMAS-8) is a valid instrument containing eight questions and can be 
completed in a routine clinic visit (See Table 3). The MMAS-8 allows healthcare providers to 
take an initial step to identify patients who are non-adherent or at risk for non-adherence to oral 
medications in adult patients with IBD (Trindade, Ehrlich, Kornbluth, & Ullman, 2011). This 
scale was not used in the studies reviewed. 
However, if adherence appears to be of pressing concern in a routine follow-up visit, 
FNPs might consider using the MMAS-8as an initial screening tool to assess the levels of 
adherence, because it is shorter. Depending on the levels of adherence, patients can be further 
assessed with a combination of objective and subjective measures to quantify medication 
adherence. FNPs should exercise caution in administrating this scale because it has not been 
studied in an adolescent population. 
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Assessing factors affecting adherence. Effective interventions start with an accurate 
identification of factors effecting adherence. It is important for FNPs to understand and use 
appropriate tools to identify factors affecting adherence. After baseline levels of non-adherence 
are obtained, or the FNP suspects there may be an issue with adherence, i.e., adherence rate is 
less than 80% according to the cut-off used in literature, or adherence rate is medium or low 
according to the MMAS-8, then specific factors affecting adherence should be identified with 
appropriate assessment tools. FNPs need to determine which tool to use for assessing specific 
factors in an individual patient or family. 
Tools for assessing factors affecting adherence in the twelve studies were presented in 
Chapter three. Among these tools, only the TAl provides qualitative data; the other tools 
provided quantitative data. The TAl was designed specifically to assess barriers to adherence in 
children with IBD (Hommel & Baldassano, 2010; Hommel, Odell et al., 2011). It contains eight 
questions (see Box 8) and was used at a regular clinic visit. Therefore, FNPs may use this tool as 
an initial screening tool to collect preliminary data at each clinic visit, then book a longer visit or 
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multiple visits to further complete an in-depth assessment with the MAl or other specific tools to 
identify specific factors affecting medication adherence. 
When using the T AI or other tools, FNPs need to involve adolescents and their parents or 
caregivers and to enable participants to discuss their concerns and identify barriers to adherence 
using an open-ended interview approach. Adolescents and parents may be interviewed separately 
or jointly. FNPs need to understand the advantages of each approach. When adolescents and 
parents are interviewed separately, different responses may have occurred with their own 
answers without embarrassment or inhibition. When they were interviewed together, they can be 
encouraged to identify and discuss different perspectives, during which the dynamics between 
adolescents and parents can be observed. Conducting interviews separately or jointly with 
adolescents and their parents or caregivers may be time-consuming, and may not fit into a 
regular clinic visit. However, since FNPs can be flexible in their schedules, they could book a 
longer clinic visit or multiple visits to obtain qualitative and quantitative data. 
Of importance, medication adherence to maintenance medications is a dynamic process 
in adolescents with ffiD. Assessing adherence and identifying factors affecting adherence should 
be ongoing in an individual patient and family for effective and efficient interventions. 
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Table 3. The Morisky medication adherence scale (MMAS-8) for IBD patients. 
Morisky Medication Adherence Scale Questions Scoring 
Yes No 
1 Do you sometimes forget to take your IBD pills? 0 1 
2 Over the past 2 weeks, were there any days when you did not take your pills for 0 1 
reasons other than forgetting? 
3 Have you ever cut back or stopped taking your pills because you felt worse 0 1 
when you took it? 
4 When you travel or leave home, do you sometimes forget to bring along your 0 1 
IBD pills? 
5 Did you take your IBD pills yesterday? 1 0 
6 When you feel like your IBD symptoms are under control, do you sometimes 0 1 
stop taking your pills? 
7 Do you ever feel hassled about sticking to your IBD treatment plan? 0 1 
8 How often do you have difficulty remembering to take Rarely/never 1 
all your IBD pills? Once in a while 0.75 
Sometimes 0.5 
Usually 0.25 
Always 0 
Low adherence <6 
Medium adherence 6-7 
High adherence 8 
(Trindade, Ehrlich, Kornbluth, & Ullman, 2011 ). 
Box 8. The treatment adherence interview for adolescents with IBD 
1. Tell me what you know about IBD in terms of how someone gets, how it is treated and 
how long someone has it. 
2. Tell me about your medication regimen and how each medication is supposed to work. 
3. How is your medication organized and who is in charge of making sure medication is 
taken? 
4. What gets in the way or prevents you from taking your medication? What makes it easier 
to take medication? 
5. Why do you think it is easy or difficult for you to take medication? 
6. When you miss a dose, whom do you tell? What happens when you tell you them? 
7. What type of relationship does you and your parents have, related to your IBD and in 
general? How do you reconcile differences? 
8. What do you think would make things less or more difficult on you and your family with 
respect to taking medications? 
(Hommel & Baldassano, 2010; Hommel, Odell, Sander, Baldassano & Barg, 2011). 
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Choosing relevant practical interventions. Adherence to maintenance medications is a 
multi-dimensional issue affected by complex and multiple factors in adolescents with IBD. Each 
patient may have one or more factors affecting medication adherence and each patient and family 
may benefit from different intervention approaches. Relevant practical interventions targeting 
specific factors are summarized for FNP practice (see Table 4). Additional explanations of 
intervention strategies will be provided in the following section. 
Interventions for disease/medication-related factors. Adolescents need to understand the 
goal of maintenance treatment and the importance of adherence to medications, even if they are 
asymptomatic in remission. FNPs need to appropriately manage medication side effects or 
adverse effects, monitor lab work as recommended for drug toxicity and consult with specialists 
or physicians for dose simplification if clinically appropriate. FNPs should work with 
adolescents together to develop practical strategies to minimize difficulty swallowing and 
symptoms associated with medication side effects, such as splitting pills, taking them with food, 
or avoiding food that can cause nausea or diarrhea. 
Interventions for psychosocial factors. Psychosocial interventions are justified with the 
BPS model in promoting medication adherence. Problematic psychosocial functioning was found 
to be associated with maladaptive behaviours and negative thinking and poor coping strategies 
and problem-solving skills. Promoting psychosocial wellbeing of adolescents and families 
improved quality of life and medication adherence (Mackner & Crandall, 2005). Supporting 
psychosocial wellbeing of adolescents and families is an integral part of psychosocial 
interventions, which was covered in the section of applying the BPS model. Other psychosocial 
interventions will be discussed in the following section. 
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Cognitive-behavioural interventions (CBI) were found to have the most empirical 
evidence for therapeutic effects on physical symptoms, depression/anxiety, behavioural and 
psychosocial issues in adolescents with ffiD. These effects were maintained during a 12-month 
period (Cook et al., 20 I 0). The intent of CBI is to empower patients through education, coping 
strategies, problem-solving skills training to effectively deal with the impact of psychosocial 
issues on medication adherence and disease management. Problem-solving skills training (PSST) 
was a promising modality used to improve medication adherence by teaching patients and 
parents a structured approach to defining problems and generating and evaluating solutions 
(Greenley et al., 2010). 
CBI and PSST are best provided by a mental health professional with training in 
understanding paediatric chronic illnesses, such as psychiatrist, therapist, social worker and 
counsellor. FNPs should make a timely referral to these health professionals for early 
psychosocial interventions in adolescents and families with psychosocial issues. Doing so will be 
beneficial for improving medication adherence. In addition to CBI and PSST, FNPs need to 
explore other effective and practical intervention strategies to facilitate psychosocial wellbeing. 
Complementary therapies have proven effective in stress coping, including exercise, 
relaxation techniques, meditation, yoga, dance, music therapy and journaling (Schneider & 
Fletcher, 2008). To help patients and families engage in practicing these techniques to reduce 
physiological and psychosocial distress, FNPs need to be aware of community resources for 
these programs and provide adolescents and parents with the information about these stress 
management techniques. FNPs may recommend the website of the Crohn's and colitis Canada to 
patients and families. This website also offers information for handling psychosocial stress and 
social network services. 
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No interventions have focused solely on social functioning and social support in 
improving medication adherence in adolescents with IBD. FNPs need to identify family coping 
strategies and availability of social support networks. FNPs work in collaboration with mental 
health professionals, social workers and community nurses to ensure that families have access to 
support resources. FNPs may refer patients and families to social workers or mental health 
professionals for early interventions, if the social distress significantly affects their psychosocial 
wellbeing and interferes with medication adherence. 
Interventions for behavioural factors. FNPs need to work with adolescents and families 
to develop practical strategies such as memory aids to improve medication taking. FNPs may 
encourage adolescents and parents to discuss perceived barriers and responsibility for medication 
taking and refilling, and make a plan for medications ahead of activities. To avoid medications 
not being refilled, FNPs may first discover any financial barriers in families and make an effort 
in assisting families to receive an appropriate coverage of medications. FNPs may collaborate 
with pharmacists for automatic medication renewals/delivery or 90 days of medication supplies 
to facilitate continuity of medication supplies. 
Memory aids should be simple, useful and individualized, such as medication dispensers, 
pharmacy bubble packs and reminders. Visual reminders include posted notes, phone text 
messages or medication charts. Patients could be reminded about taking their medications via 
simple pill-taking cues, such as placing pills close to something they use daily, e.g., toothpaste, 
breakfast table, glasses, contact lenses case, night-time beverage, etc. Auditory reminders can be 
alarm set-up, phone or video calls or voice messages. Most adolescents have a smart phone. 
FNPs can encourage them to program their phones for specific reminders tailored to patient 
preferences. Reminder systems with specific information about which medication is to be taken 
at a given time, along with dosing instructions, are likely to be most beneficial for adolescents 
who forget to take medications (Greenley, Stephens et al., 2013). 
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Reward systems or behavioural contracting was particularly helpful for adolescents with 
oppositional behaviours and/or low motivation to adhere to medications (Hommel, Herzer et al., 
2011; Hommel et al., 20 12). They suggested that behavioural contracting should be developed 
with the input of adolescents to enhance their motivating values. Rewards for taking medications 
should provide concrete reinforcement for engaging in a task. Rewards can take the forms of 
objects or privileges, and should be tied to attainable and positive goals rather than unattainable 
goals or loss of privileges. 
Interventions for modifying knowledge and beliefs. Assessment of the levels of 
education and health literacy of adolescents and parents should be an initial step required for 
effective educational interventions. Health literacy is defined the degree to which people are able 
to access, understand, evaluate and communicate information to promote and maintain good 
health across the life-course (Kwan, Frankish, & Rootman, 2006). FNPs need to adapt an 
individually tailored approach to educational interventions based on the levels of education and 
health literacy of patients and parents. FNPs may also consider a group-based educational 
intervention if it is in the best interest of patients and families, as it is generally cost-effective and 
allows for social networking among patients and families. 
Infrequent clinic visits of adolescents were recognized associated with non-adherence 
(Kitney et al., 2009), FNPs should make an effort in increasing the frequency of clinical visits for 
adolescents who have difficulty with medication adherence, and building a professional rapport 
with adolescents and their parents. FNPs or clinic assistants or other members such as RNs 
73 
should phone or text adolescents/parents in advance to remind them of the time of appointments 
and encourage them to attend educational programs for improving medication adherence. 
Written information should be provided when reinforced verbally in educational 
interventions. Patients who received written information with verbal reinforcement were more 
likely to adhere to therapy than those receiving written information alone (Hawthorne et al., 
2008). Detailed information about the names of medications, dosing schedules and mechanisms 
of action, medication side effects, potential adverse effects and the goal of maintenance 
treatment should be provided in written or verbally. Part of educational interventions could also 
be accomplished through the development of a patient handbook that addresses their concerns 
with respect to medications and treatment. 
FNPs may use different approaches to educational interventions. FNPs should consider 
routine visits as an excellent teaching and learning environment, and book longer visits as 
needed. The formal educational program designed and delivered by a gastroenterologist nurse 
practitioner (Waters et al., 2005) and the IBD-focused motivational interviewing counselling 
delivered by a RN (Cook et al., 2010) demonstrated the feasibility and acceptability in improving 
medication adherence. These IBD-focused educational interventions can be applied to FNP 
practice. 
Today, internet is one popular medium that adolescents use often. FNPs may consider 
utilizing a tele-health approach to adolescents and families whose schedules do not fit regular 
clinical visits or for whom long travel may be a burden. A web-guided approach is feasible and 
cost effective in improving adherence to maintenance medications and healthcare resources 
utilization. The numbers that patients contacted their web doctor saved 189 euro per patient per 
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year for clinic services (Elkjaer et al., 2010), which is about 265 Canadian dollars per patient per 
year. 
In summary, given that there is no single factor affecting adherence in adolescents with 
IBD, it makes a sense that no one generic intervention can be identified. Rather, evidence 
indicates that proper multi-informant assessment of key factors affecting adherence based on the 
BPS framework increases the likelihood of selecting appropriate effective, evidence-informed 
interventions that are inclusive of consideration to patient and family preferences. 
No single intervention strategy or package of strategies can be effective across all 
patients and families, conditions or settings. To accomplish this, FNPs need to choose relevant 
interventions targeting specific factors and tailored to each individual patient and family's 
situations. Given the complex and multiple factors affecting medication adherence, multi-
component interventions are likely to be superior to any single intervention in promoting 
medication adherence in adolescents. Adherence to maintenance medications is a dynamic 
process in adolescents with IBD. Therefore, reassessing adherence and outcomes of interventions 
should be ongoing in routine practice in conjunction with this stepwise approach to medication 
adherence. 
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Table 4. Factors affecting adherence and relevant practical interventions 
Factors for non-adherence Practical interventions 
Disease/medication-related factors: • IBD formal education program 
• Patient being asymptomatic in remission • Dose simplification: once or twice daily if 
• Medication complex regimens clinically appropriate 
• Side effects or adverse events of • Manage side effects: headache, anorexia, 
medications nausea, vomiting, abdominal pain 
• Difficulty swallowing pills due to the size • Monitor lab work regularly for drug toxicity 
and taste of pills • Split pills and take them with food 
Psychosocial factors: • Cognitive-behavioural interventions 
Adolescent related • Problem solving skills training 
• Anxiety • Adolescent social support group 
• Depressive symptoms • IBD camps or activity groups 
• Helplessness • Increase the frequency of clinical visits 
• Dependency • Manage anxiety and depression 
• Low self -esteem • Refer to a mental health team/social worker 
Family related: 
• Promote adaptive coping strategies 
• Family dysfunction • Shared family responsibility for medications 
• Parent-child conflicts • Sustain maternal involvement 
• Less maternal involvement • Family social support/ network 
Behavioural factors: • Use reminder systems: visual and auditory 
• Use pillbox organizers: daily, weekly 
• Forgetfulness • Blister packages 
• Interference with activities • Plan medications ahead of activities 
• Not being home • Automatic renewaVdelivery or 90 days of 
• Medications not being refilled supplies of medications 
• Attention and conduct problems • Discuss and identify financial barriers 
• Oppositional behaviours • Use behavioural contracting or reward 
systems for adolescents with oppositional 
behaviours (stickers, privileges, positive 
concrete reinforcement, attainable goals) 
Factors related to knowledge and beliefs: • Assess levels of education and health literacy 
of patients and parents 
• A lack of knowledge about IBD treatment • IBD formal education program 
and medications • Enhance patient-provider relationship 
• Beliefs that treatment was not necessary • Increase the frequency of clinical visits 
or medications were ineffective 
• Discuss beliefs and concerns about treatment 
• Concerns of medication side effects or and medications 
adverse events • Convey a non-judgmental understanding of 
the patient's perspectives 
• No blame but support 
76 
Implications and Recommendations for FNP Education 
Given the multi-factorial and complex factors affecting medication adherence in 
adolescents with ffiD, promoting medication adherence presents challenges in FNP knowledge 
and skills. Of the eight studies of intervention strategies for improving medication adherence, 
interventions were delivered by the healthcare professionals who had specific training or higher 
levels of clinical psychology, such as gastroenterology nurse practitioner, a RN who received 
CBT and motivational interviewing counselling training, or master-or doctoral-level psychology 
clinicians. This implies that FNPs need to continue receiving specific education and training to 
be competent in fulfilling the role in promoting medication adherence. 
To provide effective patient education and counselling, FNPs need to explain the concept 
of maintenance treatment and justify the need for maintaining remission and maximizing 
medication adherence. FNPs need to ensure that adolescents and parents understand the detailed 
information, such as the names of medications, dosing regimens and mechanisms of action, 
medication side effects potential adverse events, goals of maintenance treatment and 
consequences of non-adherence. With the philosophy of primary health care, FNPs are expected 
to take a leadership role in promoting medication adherence and preventing relapses of the 
disease. To accomplish the role, FNPs need to receive sufficient education on medication 
adherence and have access to specific training in adherence management. 
FNPs will seek out opportunities to expand knowledge and improve skills, such as 
attending conferences, in-services and continuing education programs, to be competent in 
management of medication adherence, conducting multi-formant adherence assessment, 
identifying factors affecting adherence and delivering relevant interventions tailored to 
individual patient and family's preferences. The healthcare organizations in which they work 
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should design and support delivery systems that empower healthcare professionals an adherence 
toolkit. 
With appropriate knowledge and skills, not only can FNPs be able to provide education 
for adolescents and parents, but also they will be an important resource for other healthcare 
professionals in promoting medication adherence. Within a multidisciplinary team, FNPs should 
raise the significance of addressing non-adherence in adolescents with IBD and share 
knowledge, information and intervention strategies for improving medication adherence. The 
knowledge and skills of improving medication adherence will also benefit FNPs in promoting 
medication adherence in adolescents with other chronic diseases. 
Implications and Recommendations for Research 
The literature review is restricted by the paucity of studies on medication adherence in 
adolescents with IBD, but fmdings of the review present some challenges and variations, which 
warrants future studies. Implications and recommendations for research will be provided in this 
section. 
Defming and assessing adherence to maintenance medication is one of the challenges. 
For maintenance medications, the level of adherence necessary to achieve a clinical remission is 
not fully known. There is no operational definition to distinguish arbitrary cut-off of adherence 
from non-adherence, although the majority of the studies of adherence considered 80% as cut-
off. There is no clinical significance to this arbitrary cut-off (Leleiko et al., 20 13). Whether 80% 
adherence is enough or I 00% adherence is necessary has not been identified. Research needs to 
define the level of adherence to sustain clinical remission or whether the cut-off adherence 
depends on how individual patients metabolize medications. 
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Another challenge presents in measurement of medication adherence, which varied 
among the studies and might result in inconsistent fmdings. Self-reports were commonly used as 
a primary assessment of adherence. Research needs to reveal data from combined measures of 
subjective and objective assessments of medication adherence. The MMAS-8 is a valid scale of 
assessing levels of medication adherence among adults with ffiD, but its validity and reliability 
need to be investigated in adolescents with ffiD. 
As previously discussed, the majority of studies on factors affecting adherence provided 
quantitative data with the tools that utilized a forced-choice format of commonly endorsed 
barriers related to adherence. Factors were assessed with qualitative or mixed data in only two 
studies (Hommel & Baldassano, 201 0; Hommel, Odell et al., 2011 ). Use of an open-ended 
interview format for qualitative data analyses may have provided greater breath of data in regard 
to specific factors affecting adherence in an individual patient and family. Research needs to 
obtain both quantitative and qualitative data to identify factors affecting adherence, combining a 
quantitative forced-choice questionnaire and a qualitative open-ended interview assessment. 
The majority of studies had a small sample size with homogeneous geographic 
characteristics, such as Caucasians. This is likely influenced by the fact that Caucasians are 
disproportionally diagnosed with IBD. Homogeneous samples of Caucasian families with higher 
levels of annual income may not easily generalize fmdings to minority and low income families. 
Socio-economic situations should be explored in research of medication adherence in an 
adolescent population. In addition, cross-sectional data were exclusively utilized in the studies on 
factors affecting adherence. This precludes the ability to make conclusions concerning the 
directionality of the fmdings. Findings revealed that older adolescents had higher non-adherence 
rates and more psychosocial issues. Longitudinal research is needed to identify casual 
relationships between factors and medication adherence, especially in older adolescents. 
79 
Current studies were focused on primary care practice and examined from the view of 
physicians. Examination on non-adherence from the view of nursing, the philosophy of primary 
health care with a BPS approach is needed in research. In addition, little research has been 
conducted on the effects ofhealthcare provider-related and healthcare system-related factors on 
adherence. Whether non-adherence is linked to these factors in adolescents with IBD needs to be 
investigated in research. 
Although the benefits from appropriate maintenance therapy throughout childhood and 
adolescence are considerable, the views on the duration for maintenance treatment in IBD 
patients remain varying among physicians, particularly in patients with quiescent UC (Zheng & 
Kennedy, 2009). This may have an impact on adherence management and disease outcomes. 
Only one study reported non-adherence to 5-ASA resulted in relapse in 61% of patients over 2 
years in adults with quiescent UC (Kane et al., 2003). No studies have reported the impacts of 
non-adherence to maintenance medications on disease activity in children and adolescent 
populations. Relapse rates with regard to duration of medication adherence in adolescents with 
IBD should be investigated. 
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Conclusion 
This paper provided an initial review on the issue of non-adherence to oral maintenance 
medications in adolescents with IDD. Twelve studies were reviewed for identifying factors 
affecting medication adherence and eight studies were reviewed for exploring intervention 
strategies for improving medication adherence in this population. Findings of this paper are 
limited by the paucity of literature on this issue. However, they provide implications for FNP 
practice, education and research in promoting medication adherence. 
The BPS model assists FNPs to examine non-adherence in adolescents with a 
comprehensive approach. With the BPS perspectives, FNPs gain a better understanding of 
factors affecting medication adherence, the significance of psychosocial issues related to 
medication adherence and the interactions of the disease/medication related, behavioural and 
psychosocial factors. To optimize medication adherence, the impact of psychosocial issues of 
adolescents and families on medication adherence should be addressed. FNPs play an important 
role in providing psychosocial interventions and supporting the psychosocial wellbeing of 
adolescents and families. In collaborative practice, FNPs cooperate with patients/families and 
healthcare providers, consult physicians, specialists and other healthcare professionals and refer 
patients to multidisciplinary professionals for early psychosocial assessments and interventions. 
A stepwise approach to medication adherence is recommended for FNP practice. An 
initial step is to measure medication adherence using both subjective and objective methods. At a 
routine visit, medication adherence may be initially screened with the MMAS-8, and then can be 
estimated with a combined method of subjective and objective measurements, such as the MAM 
and urinary levels of AS A. If non-adherence is identified or suspected, specific factors affecting 
adherence should be identified with appropriate assessment tools. 
There are several validated and reliable tools used for identifying disease/medication-
related, behavioural and psychosocial factors, assessing family psychosocial functioning, 
knowledge and beliefs of treatment and medications. FNPs need to understand these tools and 
use them appropriately for accurate assessments of factors affecting adherence. Among those 
assessment tools used in literature, the TAl, the MAl and the ffiD-FRQ were designed 
specifically for adolescents with ffiD. The TAl provides qualitative data and can be used at a 
routine clinic visit as an initial screening tool to collect preliminary information. An in-depth 
assessment with appropriate tools to identifying specific factors will be completed with in a 
longer visit or multiple visits. 
Precise assessment of factors affecting adherence is required for effective and efficient 
interventions. Behavioural, educational, psychosocial and multi-component interventions were 
provided in literature. No single intervention strategy has been shown to be effective for all 
patients. A combination of multiple intervention strategies tailored to individual patient and 
family's preferences appears a promising intervention strategy. In adolescents with ffiD, 
medication adherence is a dynamic process. An ongoing reassessment of adherence and 
outcomes of interventions with a stepwise approach is recommended. 
Promoting medication adherence challenges FNP knowledge, skills and practice. To 
accomplish the role in promoting medication adherence, FNPs need to continue receiving 
specific education and training to improve their capacity and competence. FNPs are expected 
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to be an educator, an advocate and a coordinator in management of medication adherence. FNPs 
take a leadership role and are expected to participate in research to develop effective 
interventions that are feasible and manageable in FNP practice. Investigating whether factors of 
healthcare providers and/or healthcare system are associated with non-adherence will be a value-
added component of research that FNPs contribute to improve medication adherence in 
adolescents with IBD. 
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